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A B S T R A C T
Background
Constipation within childhood is an extremely common problem. Despite the widespread use of osmotic and stimulant laxatives by
health professionals to manage constipation in children, there has been a long standing paucity of high quality evidence to support this
practice.
Objectives
We set out to evaluate the efficacy and safety of osmotic and stimulant laxatives used to treat functional childhood constipation.
Search methods
We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and the Cochrane IBD Group Specialized
Trials Register from inception to 10 March 2016. There were no language restrictions. We also searched the references of all included
studies, personal contacts and drug companies to identify studies.
Selection criteria
Randomised controlled trials (RCTs) which compared osmotic or stimulant laxatives to placebo or another intervention, with partic-
ipants aged 0 to 18 years old were considered for inclusion. The primary outcome was frequency of defecation. Secondary endpoints
included faecal incontinence, disimpaction, need for additional therapies and adverse events.
Data collection and analysis
Relevant paperswere identified and two authors independently assessed the eligibility of trials, extracted data and assessedmethodological
quality using the Cochrane risk of bias tool. The primary outcome was frequency of defecation. Secondary endpoints included faecal
incontinence, disimpaction, need for additional therapies and adverse events. For continuous outcomeswe calculated themeandifference
(MD) and 95% confidence interval (CI) using a fixed-effect model. For dichotomous outcomes we calculated the risk ratio (RR) and
95% CI using a fixed-effect model. The Chi2 and I2 statistics were used to assess statistical heterogeneity. A random-effects model was
used in situations of unexplained heterogeneity. We assessed the overall quality of the evidence supporting the primary and secondary
outcomes using the GRADE criteria.
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Main results
Twenty-five RCTs (2310 participants) were included in the review. Fourteen studies were judged to be at high risk of bias due to lack of
blinding, incomplete outcome data and selective reporting. Meta-analysis of two studies (101 patients) comparing polyethylene glycol
(PEG) with placebo showed a significantly increased number of stools per week with PEG (MD 2.61 stools per week, 95% CI 1.15 to
4.08). Common adverse events in the placebo-controlled studies included flatulence, abdominal pain, nausea, diarrhoea and headache.
Participants receiving high dose PEG (0.7 g/kg) had significantly more stools per week than low dose PEG (0.3 g/kg) participants (1
study, 90 participants, MD 1.30, 95% 0.76 to 1.84). Meta-analysis of 6 studies with 465 participants comparing PEG with lactulose
showed a significantly greater number of stools per week with PEG (MD 0.70 , 95% CI 0.10 to 1.31), although follow-up was short.
Patients who received PEG were significantly less likely to require additional laxative therapies. Eighteen per cent (27/154) of PEG
patients required additional therapies compared to 31% (47/150) of lactulose patients (RR 0.55, 95% CI 0.36 to 0.83). No serious
adverse events were reported with either agent. Common adverse events in these studies included diarrhoea, abdominal pain, nausea,
vomiting and pruritis ani. Meta-analysis of 3 studies with 211 participants comparing PEG with milk of magnesia showed that the
stools per week were significantly greater with PEG (MD 0.69, 95% CI 0.48 to 0.89). However, the magnitude of this difference was
quite small and may not be clinically significant. One child was noted to be allergic to PEG, but there were no other serious adverse
events reported. One study found a significant difference in stools per week favouring milk of magnesia over lactulose (MD -1.51,
95% CI -2.63 to -0.39, 50 patients), Meta-analysis of 2 studies with 287 patients comparing liquid paraffin (mineral oil) with lactulose
revealed a relatively large statistically significant difference in the number of stools per week favouring liquid paraffin (MD 4.94 , 95%
CI 4.28 to 5.61). No serious adverse events were reported. Adverse events included abdominal pain, distention and watery stools. No
statistically significant differences in the number of stools per week were found between PEG and enemas (1 study, 90 patients, MD
1.00, 95% CI -1.58 to 3.58), dietary fibre mix and lactulose (1 study, 125 patients, P = 0.481), senna and lactulose (1 study, 21 patients,
P > 0.05), lactitol and lactulose (1 study, 51 patients, MD -0.80, 95% CI -2.63 to 1.03), hydrolyzed guar gum and lactulose (1 study,
61 patients, MD 1.00, 95% CI -1.80 to 3.80), PEG and flixweed (1 study, 109 patients, MD 0.00, 95% CI -0.33 to 0.33), PEG and
dietary fibre (1 study, 83 patients, MD 0.20, 95% CI -0.64 to 1.04), and PEG and liquid paraffin (2 studies, 261 patients, MD 0.35,
95% CI -0.24 to 0.95).
Authors’ conclusions
The pooled analyses suggest that PEG preparations may be superior to placebo, lactulose and milk of magnesia for childhood consti-
pation. GRADE analyses indicated that the overall quality of the evidence for the primary outcome (number of stools per week) was
low or very low due to sparse data, inconsistency (heterogeneity), and high risk of bias in the studies in the pooled analyses. Thus, the
results of the pooled analyses should be interpreted with caution because of quality and methodological concerns, as well as clinical
heterogeneity, and short follow-up. There is also evidence suggesting the efficacy of liquid paraffin (mineral oil). There is no evidence
to demonstrate the superiority of lactulose when compared to the other agents studied, although there is a lack of placebo controlled
studies. Further research is needed to investigate the long term use of PEG for childhood constipation, as well as the role of liquid
paraffin. The optimal dose of PEG also warrants further investigation.
P L A I N L A N G U A G E S U M M A R Y
Laxatives for the management of childhood constipation
What is childhood constipation?
Functional childhood constipation is a common problem. The term functional constipation is used when no underlying organic cause
can be identified for the symptoms. Symptoms typically include decreased frequency of bowel movements, faecal incontinence and
a change in consistency of stools. Despite the widespread use of laxatives by health professionals to manage constipation in children,
there has been a long standing lack of evidence to support this practice.
Review question
The primary objective was to evaluate the effectiveness and side effects of osmotic and stimulant laxatives used for the treatment of
functional childhood constipation.
What are osmotic and stimulant laxatives?
Osmotic laxatives are medications that draw water into the stool, resulting in softer stools and more frequent, easier to pass bowel
movements. Some commonly used osmotic laxatives include polyethylene glycol (PEG), milk of magnesia, and lactulose. Stimulant
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laxatives induce bowel movements by increasing the contraction of muscles in the intestines. Examples of stimulant laxatives include
aloe, cascara, senna compounds, bisacodyl, and castor oil.
What did the researchers investigate?
The researchers studied whether osmotic and stimulant laxatives are effective for the treatment of childhood constipation whether these
medications cause any harms (side effects). The investigators searched the medical literature extensively up to 10 March June 2016.
What did the researchers find?
This review included 25 studies with a total of 2310 children that compared ten different agents to either placebo (inactive medications)
or each other. Many of the studies were small in size and were judged to be of poor or unclear quality. The results of this review
suggest that PEG preparations may increase the frequency of bowel movements in constipated children. There is evidence from one
study that suggests that high dose PEG (0.7 g/kg) may be superior to low dose PEG (0.3 g/kg) for increasing the frequency of bowel
movements in constipated children. The rates of minor side effects were generally lower compared to other agents. Common side effects
included flatulence, abdominal pain, nausea, diarrhoea and headache. There was also some evidence that liquid paraffin (mineral oil)
increased the frequency of bowel movements in constipated children. Common side effects with liquid paraffin included abdominal
pain, distention and watery stools. There was no evidence to suggest that lactulose is superior to the other agents studied, although
there were no trials comparing it to placebo (a fake medicine such as a sugar pill). These studies were relatively short in duration and so
it is difficult to assess the long term effectiveness of these agents for the treatment of childhood constipation. Long term effectiveness
is important, given the often chronic nature of this problem in children.
The results of the review should be interpreted with caution due to quality issues in the included studies. As such, the strength of our
conclusions is extremely limited and more research is needed. Key questions that need addressing include the safety of liquid paraffin,
given its apparent effectiveness, but limited investigation. In particular, future research should compare liquid paraffin to PEG. The
optimal dose of PEG warrants further investigation. The role of PEG for the long term management of chronic constipation also
needs further investigation to allow research to better inform actual clinical practice. There is a lack of studies comparing lactulose with
placebo.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
PEG versus placebo for the management of childhood constipation
Patient or population: pat ients aged 0 to 18 years with a diagnosis of funct ional const ipat ion
Settings: outpat ient
Intervention: PEG versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control PEG versus placebo
Frequency of defeca-
tion (mean number of
bowel movements per
week)
The mean number
of bowel movements
ranged across the
placebo groups f rom 1.
6 to 2.4 per week
The mean number of
bowel movements in
the PEG group was on
average 2.61 higher per
week (95% CI 1.15 to 4.
08)
101
(2 studies)
⊕⊕©©
low1,2
Serious adverse events 83 per 1000 3 1 5 per 1000
(2 to 126 )
RR 0 .18
(0.0 2 to 1 .51 )
101
(2 studies)
⊕⊕©©
low4
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level due to sparse data (101 pat ients).
2 Downgraded one level due to inconsistency (moderate stat ist ical heterogeneity I2 = 58%).
3 Control group risk comes f rom control arm of meta-analysis, based on included trials.4
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B A C K G R O U N D
Description of the condition
Constipation within childhood is an extremely common problem
(Van den Berg 2006), representing the chief complaint in 3% of
visits to general paediatric clinics and as many as 30% of visits to
paediatric gastroenterologists (Partin 1992). The term functional
constipation is used when no underlying organic cause can be
identified for the symptoms. Creating a workable diagnostic clas-
sification for functional constipation has proven difficult. Criteria
vary, but are mostly based on a variety of symptoms, including
decreased frequency of bowel movements, faecal incontinence and
a change in consistency of stools (Pijpers 2008).
A team of paediatricians met in 1997 in Rome to standardize the
diagnostic criteria for various functional gastroenterological dis-
orders in children. The first paediatric Rome II criteria were pub-
lished in 1999 (Rasquin-Weber 1999) and were updated during
the Rome III process in 2006, producing guidance for functional
constipation for neonates, toddlers and children (Hyman 2006;
Rasquin 2006).
To diagnose constipation using the Rome III criteria, at least two
of the symptoms below must be present for at least one month
in infants and children up to age four and at least two months in
children over four, with insufficient criteria for the diagnosis of
irritable bowel syndrome:
• Two or fewer defecations per week;
• At least one episode per week of incontinence after the
acquisition of toileting skills;
• History of retentive posturing or excessive voluntary stool
retention (over 4 years) or excessive stool retention (under 4
years);
• History of painful or hard bowel movements;
• Presence of a large faecal mass in the rectum; and
• History of large diameter stools which may obstruct the
toilet.
Effective management of childhood functional constipation de-
pends on securing a therapeutic alliance with the parents, particu-
larly through the first years when children cannot accurately report
symptoms. Clinicians depend on the reports and interpretations
of the parents, who know their child best, and their own training
and experience to differentiate between health and illness (Hyman
2006).
Description of the intervention
Laxative therapies are often the mainstay of medical therapy used
in children suffering with functional constipation, alongside adju-
vant therapies such as dietary and behavioural modification. Os-
motic laxatives, such as lactulose, milk of magnesia and polyethy-
lene glycol (PEG), are usually supplied as solutions or powders to
be dissolved in water and are therefore relatively easy to admin-
ister to young children. Stimulant laxatives, such as Senna and
Bisacodyl, come in a variety of forms, including tablets, liquids,
and suppositories.
How the intervention might work
Osmotic laxatives are poorly absorbed in the gut. They act as hy-
perosmolar agents, increasing water content of stool and therefore
making stool softer and easier to pass, as well as increasing colonic
peristalsis. Stimulant laxatives act on the intestinal mucosa, in-
creasing water and electrolyte secretion. They also stimulate peri-
staltic action.
Why it is important to do this review
Despite the widespread use of these medications by health pro-
fessionals to manage constipation in children, there has been a
long standing paucity of high quality evidence to support this
practice. Previous efforts have been made to produce guidance on
this topic (Baker 1999; Anonymous 2006), most recently by the
National Institute for Health and Clinical Excellence in the UK
(Anonymous 2010).
In recent years, the widespread introduction of PEG to paediatric
practice has led to a resurgence in research on paediatric constipa-
tion. Some studies have suggested that PEG has greater efficacy
when compared with placebo (Thomson 2007), as well as when
compared to lactulose (Voskujl 2004; Candy 2006).
A recently published Cochrane review investigated the specific
comparison of PEG versus lactulose in children and adults
(Lee-Robichaud 2010). There currently exists no other systematic
review using the Cochrane collaboration format for the use of os-
motic laxatives in children. A previous Cochrane review evaluat-
ing the effect of stimulant laxatives on constipation in children
found no studies of sufficient quality to allow evaluation (Price
2001). An up to date systematic review using the Cochrane Col-
laboration format is indicated to summarise the current evidence
on the use of osmotic and stimulant laxatives for the management
of constipation in children. This systematic review is an update of
a previously published Cochrane review (Gordon 2012; Gordon
2013).
O B J E C T I V E S
The primary objectives are to evaluate the efficacy and safety of
osmotic and stimulant laxatives used to treat functional childhood
constipation.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials were considered for inclusion.
Types of participants
Patients aged 0 to 18 years with a diagnosis of functional constipa-
tion, with or without incontinence were considered for inclusion.
The diagnosis of constipation was patient self-reported, physician
diagnosed, or by consensus criteria (e.g. Rome III). Studies with
patients suffering from any underlying pathology, such as thyroid
abnormalities, Hirschsprung’s disease or having undergone previ-
ous bowel surgery at study entry, were excluded.
Types of interventions
Studies comparing osmotic or stimulant laxatives with another in-
tervention or placebo were considered for inclusion. All prepara-
tions and dosing regimes were considered. Studies using multiple
osmotic or stimulant laxative combinations or combinations of
both as their intervention were also considered for inclusion.
Types of outcome measures
Primary outcomes
The primary outcome measure was the frequency of defecation
(number of stools per week).
Secondary outcomes
Secondary outcomes included:
1) Faecal incontinence;
2) Disimpaction;
4) Need for additional therapies; and
5) Adverse events.
Search methods for identification of studies
Electronic searches
A computer-assisted search for relevant studies (from database in-
ception to 10 March 2016) was performed using MEDLINE,
EMBASE and the Cochrane Central Register of Controlled Tri-
als and the Cochrane IBD Group Specialized Register (Appendix
1). References from published articles and conference proceedings
were searched to identify additional citations.
There is some evidence that data from abstracts can be inconsistent
with data in published articles (Pitkin 1999), therefore abstract
publications were not included in this review.
Searching other resources
B. Reference searching
The references of all identified studies were inspected for more
trials.
C. Personal contacts
Leaders in the field were contacted to try to identify other studies.
D. Drug companies
The manufacturers of osmotic and stimulant laxative agents were
contacted for additional data.
Data collection and analysis
All identified abstracts and results from searches were reviewed by
two authors (MG and KN). If the reference appeared relevant, a
full copy of the study was obtained.
Selection of studies
Two authors (MG and KN), after reading the full texts, indepen-
dently assessed the eligibility of all trials identified based on the in-
clusion criteria above. Disagreement among authors was discussed
and agreement reached by consensus.
Data extraction and management
A data extraction form was developed and piloted to extract infor-
mation on relevant features and results of included studies. The
two reviewers separately extracted and recorded data on the pre-
defined checklist.
Extracted data included the following items:
a. characteristics of patients: age, sex, duration of symptoms;
b. study methods, total number of patients originally assigned to
each treatment group;
c. intervention: preparations, dose, administration regime;
d. control: placebo, other drugs;
e. concurrent medications;
f. outcomes (time of assessment, length of follow-up, frequency
of defecation, pain on defecation and/or straining, faecal incon-
tinence, stool consistency, need for additional therapies, num-
ber and type of adverse events associated with treatment, adverse
events); and
g. withdrawals and reasons for withdrawals.
Assessment of risk of bias in included studies
The methodological quality of selected trials was assessed inde-
pendently by two authors using the Cochrane risk of bias tool
(Higgins 2011a). Factors assessed included:
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1. sequence generation (i.e. was the allocation sequence
adequately generated?);
2. allocation sequence concealment (i.e. was allocation
adequately concealed?);
3. blinding (i.e. was knowledge of the allocated intervention
adequately prevented during the study?);
4. incomplete outcome data (i.e. were incomplete outcome
data adequately addressed?);
5. selective outcome reporting (i.e. are reports of the study free
of suggestion of selective outcome reporting?); and
6. other potential sources of bias (i.e. was the study apparently
free of other problems that could put it at a high risk of bias?).
A judgement of ’Yes’ indicates low risk of bias, ’No’ indicates high
risk of bias, and ’Unclear’ indicates unclear or unknown risk of
bias. Disagreements was resolved by consensus. Study authors were
contacted for further information when insufficient information
was provided to determine the risk of bias.
We used the GRADE approach for rating the overall quality of
evidence for the primary outcome. Randomised trials start as high
quality evidence, but may be downgraded due to: (1) risk of bias,
(2) indirectness of evidence, (3) inconsistency (unexplained het-
erogeneity), (4) imprecision (sparse data), and (5) reporting bias
(publication bias). The overall quality of evidence for each out-
comewas determined after considering each of these elements, and
categorized as high quality (i.e. further research is very unlikely to
change our confidence in the estimate of effect); moderate quality
(i.e. further research is likely to have an important impact on our
confidence in the estimate of effect and may change the estimate);
low quality (i.e. further research is very likely to have an important
impact on our confidence in the estimate of effect and is likely to
change the estimate); or very low quality (i.e. we are very uncertain
about the estimate) (Guyatt 2008; Schünemann 2011).
Measures of treatment effect
For the primary outcome, frequency of defecation, we calculated
the mean difference (MD) and corresponding 95% confidence
interval (CI). For the secondary dichotomous outcomes we calcu-
lated the risk ratio (RR) and corresponding 95% CI.
Dealing with missing data
The authors of included studies were contacted to supply any
missing data.
Assessment of heterogeneity
Heterogeneity among trial results was assessed by visual inspection
of forest plots and by calculating the Chi2 square test for hetero-
geneity (a P value of 0.10 was regarded as statistically significant).
We also used the I2 statistic to quantity the effect of heterogeneity
(Higgins 2003). A random-effects model was used in situations
of unexplained heterogeneity. We aimed to further investigate po-
tential sources of heterogeneity.
Assessment of reporting biases
If an appropriate number of studies was found, we aimed to inves-
tigate the possibility of a publication bias through the construction
of funnel plots (trial effects versus trial size).
Data synthesis
For outcomes that were sufficiently homogenous, meta-analysis
was carried out using a fixed-effectmodel. A random-effectsmodel
was used in situations of unexplained heterogeneity.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses were to be carried out to further study the
effects of a number of variables on the outcomes including:
a. whether patients were being inducted in to ‘remission’ from
constipation or whether this was a study of ‘maintenance’ therapy;
b. the effect of length of therapy / follow-up; and
c. specifically what, if any agents, were initially allowed in the
protocol to clear any impaction (such as enemas).
Sensitivity analysis
Sensitivity analyses was conducted based on the following:
a. only including patients’ whose outcome is known i.e. number
of patients who completed the study used as denominator; and
b. random-effects versus fixed-effect models.
We also planned to consider the effect of:
c. allocation concealment;
d. type of agent;
e. dose of agent; and
f. concurrent medications.
R E S U L T S
Description of studies
A literature search conducted on 10 March 2016 identified 763
studies. Four additional studies were identified through search-
ing of references. After duplicates were removed a total of 668
reports remained for review of titles and abstracts. Two authors
independently reviewed the titles and abstracts of these studies
49 studies were selected for full text review (See Figure 1). Nine-
teen reports of 18 studies were excluded (See Characteristics of
excluded studies). Thirty reports of 25 studies involving a to-
tal of 2310 patients were selected for inclusion (Bekkali 2009;
Candy 2006; Dupont 2005; Dziechciarz 2015; Farahmand 2007;
Gomes 2011; Gremse 2002; Karami 2009; Kokke 2008; Loening-
Baucke 2006; Nimrouzi 2015; Nurko 2008; Perkin 1977; Pitzalis
1995; Quitadamo 2012; Rafati 2011; Ratanamongkol 2009;
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Saneian 2012;Thomson 2007;Tolia 1993;Treepongkaruna 2014;
Urganci 2005; Ustundag 2010; Voskujl 2004; Wang 2007) (See
Characteristics of included studies).
Figure 1. Study flow diagram.
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Eighteen studies were excluded for various reasons. Five studies
were not randomised controlled trials (Dupont 2005; Hardikar
2007; Hejl 1990; Shevtsov 2005; Sonheimer 1982), two studies
included adult patients (Corazziari 1996; Ferguson 1999), one
study included adult and paediatric participants without report-
ing separate results for children (Connolly 1974), one study was
of children with soiling (Berg 1983), two studies focused on the
treatment of children with faecal impaction rather than functional
constipation (Miller 2012; Youssef 2002); one study was of chil-
dren with underlying bowel pathology (Kazak 1999); three studies
looked at combination therapy with PEG compared to PEG by
itself ( Bongers 2009; Dehghani 2014; Khoshoo 2006); one study
compared one formulation of PEG to another (Savino 2012), and
two studies were abstract publications (Bekkali 2009; Ormarsson
2013).
Two studies compared PEG to placebo (Thomson 2007; Nurko
2008), five compared PEG with lactulose (Gremse 2002; Voskujl
2004; Dupont 2005; Candy 2006; Wang 2007), three compared
PEG with milk of magnesia (magnesium oxide) (Loening-Baucke
2006, Gomes 2011, Ratanamongkol 2009), two compared liq-
uid paraffin with lactulose (Urganci 2005; Farahmand 2007) two
compared liquid paraffin with PEG (Tolia 1993; Rafati 2011),
one compared PEG with enemas (Bekkali 2009), one compared a
dietary fibre mix with lactulose (Kokke 2008), one lactulose with
senna (Perkin 1977) and one lactitol with lactulose (Pitzalis 1995).
The age of participants ranged from 6 months up to 16 years.
The duration of the studies varied from 2 weeks to 12 months.
The specific criteria for a diagnosis of constipation also varied
between studies, as did the minimum length of symptoms. All
studies excluded children with organic causes for their pathology
(see characteristics of included studies).
Risk of bias in included studies
The risk of bias analysis for the included studies is summarised in
Figure 2 and Figure 3.
Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 3. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
In nine of the included studies, the method of random alloca-
tion of participants to intervention groups was described and
was judged to be adequate (Tolia 1993; Loening-Baucke 2006;
Thomson 2007;Wang 2007; Kokke 2008; Ratanamongkol 2009;
Saneian 2012; Treepongkaruna 2014; Dziechciarz 2015). These
studies were rated as low risk of bias for sequence generation. For
one study (Candy 2006), the sponsor responded to a request for
more details and confirmed adequate sequence generation. This
study was rated as low risk of bias for sequence generation. Al-
location was described as random in the 15 remaining studies,
although the method of randomisation was not described. These
studies were rated as unclear risk of bias for sequence generation.
Allocation concealment was rated as low risk of bias in six stud-
ies (Perkin 1977; Loening-Baucke 2006; Thomson 2007; Kokke
2008; Ratanamongkol 2009; Dziechciarz 2015), and as unclear
risk of bias for the other studies.
Blinding
Methods for blinding were described and judged to be adequate in
seven studies. These studies were rated as low risk of bias for blind-
ing (Voskujl 2004; Dupont 2005; Candy 2006; Thomson 2007;
Kokke 2008; Nurko 2008; Treepongkaruna 2014). In six studies,
the use of blinding was reported but not described clearly. These
studies were rated as unclear risk of bias for blinding (Perkin 1977;
Pitzalis 1995;Wang 2007; Ratanamongkol 2009;Ustundag 2010;
Rafati 2011). Saneian 2012 did not describe the use of blind-
ing but clearly reported that no patients received placebo. This
study was rated as high risk of bias for blinding. The remaining
11 studies were described as open label or single-blind and were
rated as high risk of bias for blinding (Tolia 1993; Gremse 2002;
Urganci 2005; Loening-Baucke 2006; Farahmand 2007; Bekkali
2009; Karami 2009; Gomes 2011; Quitadamo 2012; Dziechciarz
2015; Nimrouzi 2015).
Incomplete outcome data
Three studies were judged to be at high risk of bias for incomplete
outcome data (Karami 2009; Gomes 2011, Rafati 2011). Four
studies were rated as unclear risk of bias because drop outs were
no adequately described (Wang 2007; Quitadamo 2012; Saneian
2012; Nimrouzi 2015). The remaining studies were judged to be
at low risk of bias because drop outs were balanced across treatment
groups with similar reasons for withdrawal or there were few drop
outs..
Selective reporting
In five studies, the authors did not report on adverse event out-
comes and therefore these studies were judged to be at risk of bias
for selective reporting (Pitzalis 1995; Gremse 2002; Bekkali 2009;
Gomes 2011; Rafati 2011). One study was judged to be at unclear
risk of bias because adverse events were not adequately reported.
The remaining studies were judged to be at low risk of bias for
selective reporting.
Other potential sources of bias
None of the studies appeared to have any other potential sources
of bias other than industry funding. All of the studies were rated
as low risk of bias for other potential sources of bias. One study
stated that they were supported by a pharmaceutical company, but
details of the extent of involvement were unclear (Candy 2006).
Two studies were sponsored by pharmaceutical companies, but
confirmation was received that industry had no involvement in the
conduct of the studies or the writing up of the results (Thomson
2007; Nurko 2008).
Effects of interventions
See: Summary of findings for the main comparison PEG
versus placebo for the management of childhood constipation;
Summary of findings 2 PEG versus lactulose for themanagement
of childhood constipation; Summary of findings 3 PEG versus
milk of magnesia (MOM) for the management of childhood
constipation; Summary of findings 4 PEG versus enema
for the management of childhood constipation; Summary of
findings 5 PEG versus paraffin for the management of childhood
constipation; Summary of findings 6 PEG versus flixweed
for the management of childhood constipation; Summary
of findings 7 PEG versus dietary fibre for the management
of childhood constipation; Summary of findings 8 High
dose PEG versus low dose PEG for the management of
childhood constipation; Summary of findings 9 Liquid paraffin
(mineral oil) versus lactulose for the management of childhood
constipation; Summary of findings 10 Lactulose versus lactitol
for the management of childhood constipation; Summary of
findings 11 Lactulose versus milk of magnesia (MOM) for the
management of childhood constipation; Summary of findings
12 Lactulose versus partially hydrolyzed guar gum (PHGG) for
the management of childhood constipation
For the analyses, we used the total number of patients randomised
as the denominator. In all analyses, the frequency of defecation
was measured as stools per week.
PEG versus Placebo
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The published results for the two studies concerning 101 patients
were inadequate to allow pooling for meta-analysis. The authors
were contacted and directed us to the study sponsors who supplied
unpublished data to allow analysis for outcomes at two weeks.
One of the studies used multiple dosing regimens, but data were
obtained for the dose of 0.8 g/kg (Nurko 2008).
Efficacy
Frequency of defecation
Heterogeneity was noted to be moderate (P = 0.12, I2 = 58%) and
using a random-effects model, the MD was 2.61 stools per week
(95% CI 1.15 to 4.08), favouring PEG over placebo, see Analysis
1.1 and Figure 4. The GRADE analysis indicated that the over-
all quality of the evidence for the primary outcome (frequency of
defecation) was low due to sparse data (101 patients) and incon-
sistency (statistical heterogeneity I2 = 58%) in the pooled analysis
(See Summary of findings for the main comparison).
Figure 4. Forest plot of comparison: 1 PEG versus Placebo, outcome: 1.1 Frequency of defecation.
Episodes of faecal incontinence
At two weeks, both studies reported higher rates of faecal inconti-
nence in the PEG group. As there was some discrepancy in base-
line data between groups in one study (Nurko 2008), and the dif-
ference before and after treatment was not reported, meta-analysis
for this outcome was not completed.
Safety
Serious adverse events were not reported in the PEG groups in
either study, but were seen in the placebo groups (8% of placebo
patients experienced a serious adverse event). However, there was
no statistically significant difference in the incidence of serious
adverse events using a fixed-effectmodel (RR0.18, 95%CI 0.02 to
1.51). A sensitivity analysis using a random-effects model did not
have any impact on the results (RR0.19, 95%0.02 to1.63).Minor
adverse events were common and included flatulence, abdominal
pain, nausea, diarrhoea and headache. However, data were not
reported to allow meta-analysis. The studies both stated that no
difference in the incidence of adverse events appeared to exist
between the groups.
PEG versus Lactulose
One of the seven studies did not report data that could be used
for meta-analysis (Wang 2007). The authors were contacted, but
no response was received and so the remaining 6 studies including
465 patients were analysed. One study reported separate results for
babies and toddlers (Dupont 2005). Using the method described
in the Cochrane handbook (Higgins 2011b), the mean and stan-
dard deviation for the entire sample were estimated.
Efficacy
Frequency of defecation
Heterogeneity was noted to be high (P = 0.007, I2 = 69%) and
using a random-effects model a statistically significant difference
in favour of PEG over lactulose was seen, with a MD of 0.70
stools per week (95%CI 0.10 to 1.31), see Analysis 2.1 and Figure
5. The GRADE analysis indicated that the overall quality of the
evidence for the primary outcome (frequency of defecation) was
very low due to inconsistency (statistical heterogeneity I2 = 69%),
and a high risk of bias (i.e. lack of blinding and selective reporting)
in two studies in the pooled analysis (See Summary of findings 2).
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Figure 5. Forest plot of comparison: 2 PEG versus Lactulose, outcome: 2.1 Frequency of defecation.
Need for additional therapies
Using a fixed-effect model, there was a statistically significant re-
sult favouring PEG over lactulose. For the 4 studies (304 patients)
that reported this outcome (Voskujl 2004; Dupont 2005; Candy
2006; Saneian 2012), 18% (27/154) of PEG patients required ad-
ditional therapy compared to 31% (47/150) of lactulose patients,
(RR 0.55, 95% CI 0.36 to 0.83), see Analysis 2.2. The GRADE
analysis indicated that the overall quality of the evidence support-
ing this outcomewas lowdue high risk of bias (i.e. lack of blinding)
and sparse data (74 events; See Summary of findings 2). When
a sensitivity analysis using a random-effects model was calculated
the results were no longer statistically significant (RR 0.59, 95%
CI 0.33 to 1.04), see Analysis 2.3.
Successful disimpaction
For the one study that reported this outcome (Saneian 2012),
100% of PEG participants were successfully disimpacted com-
pared to 80% of lactulose patients (RR 1.24, 95% CI 1.01 to
1.53; P = 0.04). The GRADE analysis indicated that the overall
quality of the evidence supporting this outcome was low due to
high risk of bias (i.e. lack of blinding) and sparse data (45 events;
See Summary of findings 2).
Safety
Minor adverse events were seen in most studies, but were
not reported in one study (Gremse 2002). Common adverse
events included diarrhoea ( Saneian 2012; Wang 2007) , ab-
dominal pain (Saneian 2012; Wang 2007), bloating (Saneian
2012), nausea, vomiting (Treepongkaruna 2014), impacted fae-
ces (Treepongkaruna 2014), and pruritis ani (Treepongkaruna
2014). For the 3 studies (242 patients) that reported data allow-
ing meta-analysis (Dupont 2005; Candy 2006; Treepongkaruna
2014), there was no statistically significant difference in the pro-
portion of patients who experienced at least one adverse event.
Thirty-seven per cent (46/123) of PEG patients experienced at
least one adverse event compared to 45% (54/119) of lactulose
patients (RR 0.87, 95% CI 0.68 to 1.11), see Analysis 2.5. The
GRADE analysis indicated that the overall quality of the evidence
supporting this outcome was moderate due to sparse data (100
events; See Summary of findings 2).
Serious adverse events were reported in two studies (Candy 2006;
Treepongkaruna 2014). Candy 2006 reported a chest infection in
a patient in the PEG group, thought to be unrelated to therapy.
Serious adverse events reported in the Treepongkaruna 2014 study
include pneumonia and a traffic accident in the PEG 4000 group
and a varicella infection in the lactulose group. None of these
events were considered to be related to the study drug. There was
no statistically significant difference in the proportion of patients
who experienced a serious adverse event. Four per cent (3/71) of
PEG participants had a serious adverse event compared to 1% (1/
74) of lactulose participants (RR2.43, 95%CI 0.37 to 15.96). The
GRADE analysis indicated that the overall quality of the evidence
supporting this outcome was low due to very sparse data (4 events;
See Summary of findings 2).
PEG versus Milk of Magnesia
Four studies (261 participants) compared PEG to milk of magne-
sia (Loening-Baucke 2006; Ratanamongkol 2009; Gomes 2011;
Saneian 2012). One study reported outcomes at 1 month and 12
months (Loening-Baucke 2006). However, data for outcomes at 4
weeks were used for meta-analysis. Ratanamongkol 2009 reported
median and interquartile ranges for results and these were used to
estimate the mean and standard deviation (Hozo 2005).
Efficacy
Frequency of defecation
Using a random-effects model, there was no statistically signifi-
cant difference the frequency of defecation (MD 0.20, 95% CI -
0.68 to 1.07). However, there was significant heterogeneity in the
pooled analysis(P = 0.03, I2 = 66%). A visual inspection of the
forest plot suggests that the Saneian 2012 study is the source of
this heterogeneity. When this study was excluded in a sensitivity
analysis there was a statistically significant result favouring PEG
over milk of magnesia and the I2 value dropped to 0%. The MD
was 0.69 stools per week (95% CI, 0.48 to 0.89), see Analysis 3.1.
The GRADE analysis indicated that the overall quality of the evi-
dence for the primary outcome (frequency of defecation) was low
due to sparse data (211 patients) and a high risk of bias (i.e. lack of
blinding in one study and lack of blinding, incomplete outcome
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data and selective reporting in the other study) in two studies in
the pooled analysis (See Summary of findings 3).
Succesful disimpaction
There was no statistically significant difference in the proportion
of participants who were successfully disimpacted. Successful dis-
impaction was achieved in 100% (25/25) of PEG patients com-
pared to 96% (24/25) of milk of magnesia patients (RR 1.04, 95%
CI 0.93 to 1.16). The GRADE analysis indicated that the overall
quality of the evidence supporting this outcome was low due to
sparse data (49 events) and a high risk of bias (i.e. lack of blinding;
See Summary of findings 3).
Safety
A serious adverse event of allergy to PEG was reported in one
patient (Loening-Baucke 2006). Minor adverse events data were
not reported to allow meta-analysis. One study (Ratanamongkol
2009) noted a statistically significant difference in proportion of
patients experiencing diarrhoea. Twenty-eight per cent of patients
in the milk of magnesia group experienced diarrhoea compared to
4% of PEG patients (P = 0.002). Gomes 2011 did not explicitly
report adverse event data. Common adverse events reported in the
Saneian 2012 study included abdominal pain and bloating in the
PEG group and abdominal pain, bloating and diarrhoea in the
milk of magnesia group.
PEG versus Enemas
Bekkali 2009 compared PEG to enemas (90 participants). This
study reported outcomes at four weeks.
Efficacy
Frequency of defecation
There was no statistically significant difference in the frequency of
defecation between PEG and enema groups. The MD was 1.00
stools per week (95% CI -1.58 to 3.58). The GRADE analysis
indicated that the overall quality of the evidence for the primary
outcome (frequency of defecation) was low due to sparse data (80
patients) and a high risk of bias (i.e. lack of blinding and selective
reporting; See Summary of findings 4).
Succesful disimpaction
Successful disimpaction was reported in 80% (37/46) of enema
patients compared to 68% (30/44) of PEG patients. However, the
difference was not statistically significant (RR 0.85, 95% CI 0.66
to 1.09). The GRADE analysis indicated that the overall quality
of the evidence for the primary outcome (frequency of defecation)
was low due to sparse data (67 events) and a high risk of bias (i.e.
lack of blinding and selective reporting; See Summary of findings
4).
Safety
Adverse event data were not explicitly reported within this study,
although the authors reported significantly higher rates of faecal
incontinence and watery stools with PEG.
PEG versus Liquid paraffin
Three studies (299 participants) compared PEG to liquid paraffin
(Tolia 1993; Karami 2009; Rafati 2011). The studies had varying
lengths of follow-up. Tolia 1993 followed up patients at two days.
Karami 2009 followed patients every week for a month and then
monthly for two to four months. Rafati 2011 followed patients
weekly for the first two weeks and then monthly until 120 days.
The Tolia 1993 study was not pooled with the other two studies
because the primary outcome was not similar enough to allow
pooling.
Efficacy
Frequency of defecation
Tolia 1993 reported on the frequency of bowel movements after
treatment (scored as > 5, 1 to 5 or none). The authors reported that
PEGpatients hadmore frequent bowelmovements after treatment
than liquid paraffin patients (P < 0.005). Two studies reported on
the frequency of defecation at 30 days and were pooled for meta-
analysis (Karami 2009; Rafati 2011). There was no statistically
significant difference in the frequency of defecation (MD 0.35,
95% CI -0.24 to 0.95). The GRADE analysis indicated that the
overall quality of the evidence for the primary outcome (frequency
of defecation) was very low due to sparse data (261 patients) and a
high risk of bias in both studies in the pooled analysis (i.e. lack of
blinding and incomplete outcome data in one study and incom-
plete outcome data and selective reporting in the other study; See
Summary of findings 5).
Safety
No serious adverse events were reported. Tolia 1993 reported sig-
nificantly more vomiting in the PEG group compared to liquid
paraffin (P < 0.005). Karami 2009 reported that there were no
adverse events. Adverse events reported in the Rafati 2011 study
included nausea, vomiting, diarrhoea, flatulence, abdominal pain
and dehydration. All of these outcomes, with the exception of di-
arrhoea, were significantly more likely to occur in children who
received liquid paraffin compared to PEG.
PEG versus Flixweed
One study (109 participants) compared PEG to flixweed (
Nimrouzi 2015). Participants were assessed at three and eight
weeks.
Efficacy
Frequency of defecation
There was no statistically significant difference in the frequency
of defecation (MD 0.00, 95% CI -0.33 to 0.33). The GRADE
analysis indicated that the overall quality of the evidence for the
primary outcome (frequency of defecation) was low due to sparse
data (109 participants) and a high risk of bias (i.e. lack of blinding
and random sequence generation, allocation concealment and in-
complete outcome data were also rated as unclear; See Summary
of findings 6).
Need for additional therapy
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There was a non-significant trend (P = 0.05) favouring flixweed
over PEG for the need for additional therapy. Nineteen per cent
(10/53) of PEG participants needed additional therapy compared
to 5% (3/56) of flixweed participants (RR 3.52, 95% CI 1.03 to
12.10). The GRADE analysis indicated that the overall quality of
the evidence supporting this outcome was very low due to serious
imprecision (13 events) and a high risk of bias (i.e. lack of blind-
ing and random sequence generation, allocation concealment and
incomplete outcome data were also rated as unclear; See Summary
of findings 6).
Safety
The authors reported no difference in the proportion of patients
who experienced flatulence and abdominal pain after 8 weeks of
therapy.
PEG versus dietary fibre mix
One study (83 participants) compared PEG to dietary fibre mix
(Quitadamo 2012). Participants were assessed at one, two, four
and eight weeks.
Efficacy
Frequency of defecation
There was no statistically significant difference in the frequency
of defecation (MD 0.20, 95% CI -0.64 to 1.04). The GRADE
analysis indicated that the overall quality of the evidence for the
primary outcome (frequency of defecation) was low due to sparse
data (83 participants) and a high risk of bias (i.e. lack of blinding
and random sequence generation, allocation concealment and in-
complete outcome data were also rated as unclear; See Summary
of findings 7).
Need for additional therapy
There was no statistically significant difference in the proportion
of participants who required additional therapy for their constipa-
tion. Two per cent (1/50) of PEG participants required additional
therapy compared to 4% (2/50) of dietary fibre participants (RR
0.50, 95% CI 0.05 to 5.34). The GRADE analysis indicated that
the overall quality of the evidence supporting this outcome was
very low due to serious imprecision (3 events) and a high risk of
bias (i.e. lack of blinding and random sequence generation, allo-
cation concealment and incomplete outcome data were also rated
as unclear; See Summary of findings 7).
Faecal incontinence
There was no statistically significant difference in the frequency
of faecal incontinence (MD -0.10, 95% CI -0.62 to 0.42). The
GRADE analysis indicated that the overall quality of the evidence
supporting this outcome was low due to sparse data (83 partici-
pants) and a high risk of bias (i.e. lack of blinding and random
sequence generation, allocation concealment and incomplete out-
come data were also rated as unclear; See Summary of findings 7).
High dose PEG versus low dose PEG
One study (90 participants) compared high dose PEG (0.7 g/kg)
to low dose PEG (0.3 g/kg) (Dziechciarz 2015). Participants were
assessed six weeks.
Efficacy
Frequency of defecation
There was a statistically significant difference in the frequency of
defecation favouring high dose over low dose PEG (MD 1.30,
95% CI 0.76 to 1.84). The GRADE analysis indicated that the
overall quality of the evidence supporting the primary outcome
(frequency of defecation) was low due to sparse data (90 partici-
pants) and a high risk of bias (i.e. lack of blinding; See Summary
of findings 8).
Need for additional therapy
There was a non-significant trend (P = 0.06) favouring high dose
PEG over low dose PEG for the need for additional therapy. Eigh-
teen per cent (8/44) of high dose PEG participants needed addi-
tional therapy compared to 37% (17/46) of low dose PEG par-
ticipants (RR 0.49, 95% CI 0.24 to 1.02). The GRADE analysis
indicated that the overall quality of the evidence supporting this
outcome was very low due to serious imprecision (25 events) and
a high risk of bias (i.e. lack of blinding; See Summary of findings
8).
Faecal incontinence
Therewas no statistically significant difference in the proportion of
patients who experienced faecal incontinence. Two per cent (1/44)
of high dose PEG participants had faecal incontinence compared
to 13% (6/46) of low dose PEG participants (RR 0.17, 95% CI
0.02 to 1.39). The GRADE analysis indicated that the overall
quality of the evidence supporting this outcome was very low due
to serious imprecision (7 events) and a high risk of bias (i.e. lack
of blinding; See Summary of findings 8).
Safety
Adverse events
There was no statistically significant difference in the proportion
of patients who experienced an adverse event.Nine per cent (4/44)
of high dose PEG participants had an adverse event compared to
6% (3/46) of low dose PEG participants (RR 1.39, 95% CI 0.33
to 5.88). TheGRADE analysis indicated that the overall quality of
the evidence supporting this outcome was very low due to serious
imprecision (7 events) and a high risk of bias (i.e. lack of blinding;
See Summary of findings 8). Adverse events in the high dose PEG
group included loose stools (n = 3) and refusal of PEG (n = 1).
Adverse events in the low dose group included
Liquid Paraffin versus Lactulose
Two studies (287 participants) compared liquid paraffin to lac-
tulose (Urganci 2005; Farahmand 2007). These studies reported
outcomes at eight weeks.
Efficacy
Frequency of defecation
Using a fixed-effectmodel, there was a statistically significant result
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favouring liquid paraffin over lactulose. The MD was 4.94 stools
per week (95% CI 4.28 to 5.61) see Analysis 9.1 and Figure 6.
There was no evidence of heterogeneity in the pooled analysis (P
= 0.45, I2 = 0%). The GRADE analysis indicated that the overall
quality of the evidence for the primary outcome (frequency of
defecation) was low due to sparse data (287 patients) and a high
risk of bias (i.e. lack of blinding in both studies) (See Summary of
findings 9).
Figure 6. Forest plot of comparison: 4 Liquid Paraffin versus Lactulose, outcome: 4.1 Frequency of
defecation.
Safety
No serious adverse events were reported in either study. Minor ad-
verse events such as abdominal pain, distention and watery stools
were reported with both agents, but data were not presented in a
manner to allow meta-analysis.
Lactulose versus Lactitol
Pitzalis 1995 compared lactulose to lactitol (51 participants), This
study reported outcomes at 30 days.
Efficacy
Frequency of defecation
There was no statistically significant difference between the two
agents in the frequency of defecation. The MD was -0.80 stools
per week (95% CI -2.63 to 1.03). The GRADE analysis indicated
that the overall quality of the evidence for the primary outcome
(frequency of defecation) was low due to sparse data (42 partici-
pants) and a high risk of bias (i.e. selective reporting, random se-
quence generation, allocation concealment and blinding were also
rated as unclear; See Summary of findings 10).
Safety
Adverse events were not reported.
Lactulose versus Milk of Magnesia
One study (50 participants) also compared lactulose to milk of
magnesia (Saneian 2012). Outcomes were measured at five weeks.
Efficacy
Frequency of defecation
There was a statistically significant difference in the frequency
of defecation favouring milk of magnesia over lactulose (MD -
1.51, 95% CI -2.63 to -0.39). The GRADE analysis indicated
that the overall quality of the evidence supporting the primary
outcome (frequency of defecation) was low due to sparse data
(50 participants) and a high risk of bias (i.e. lack of blinding,
allocation concealment and incomplete outcome data were also
rated as unclear; See Summary of findings 11).
Successful disimpaction
There was no statistically significant difference in the proportion
of participants who were successfully disimpacted. Eighty per cent
(20/25) of participants in the lactulose group were successfully dis-
impacted compared to 96% (24/25) of milk of magnesia patients
(RR 0.83, 95% CI 0.67 to 1.03). The GRADE analysis indicated
that the overall quality of the evidence supporting this outcome
was low due to sparse data (44 events) and a high risk of bias (i.e.
lack of blinding, allocation concealment and incomplete outcome
data were also rated as unclear; See Summary of findings 11).
Need for additional therapy
There was no statistically significant difference in the proportion
of participants who needed additional therapy for their constipa-
tion. Forty per cent (10/25) of participants in the lactulose group
required additional therapy compared to 20% (5/25) of milk of
magnesia patients (RR 2.00, 95% CI 0.80 to 5.02). The GRADE
analysis indicated that the overall quality of the evidence support-
ing this outcome was very low due to sparse data (15 events) and
a high risk of bias (i.e. lack of blinding: See Summary of findings
11).
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Safety
Adverse events
Common adverse events reported in the Saneian 2012 study in-
cluded abdominal pain, bloating and diarrhoea in the milk of
magnesia group and abdominal pain and bloating in the lactulose
group.
Lactulose versus Partially Hydrolyzed Guar Gum
One study (61 participants) compared lactulose to partially hy-
drolyzed guar gum (Ustundag 2010). Outcomes were measured
at four weeks.
Efficacy
Frequency of defecation
There was no statistically significant difference in the frequency
of defecation (MD 1.00, 95% CI -1.80 to 3.80). The GRADE
analysis indicated that the overall quality of the evidence support-
ing the primary outcome (frequency of defecation) was low due to
sparse data (61 participants) and an unclear risk of bias (i.e. ran-
dom sequence generation, allocation concealment, blinding and
selective reporting were rated as unclear; See Summary of findings
12).
Safety
Adverse events
Flatulence was reported in the lactulose group (Ustundag 2010).
Dietary fibre mix versus Lactulose
Kokke 2008 compared dietary fibre to lactulose (125 participants).
This study reported outcomes at eight weeks.
Efficacy
Frequency of defecation
Kokke 2008 reported that there was no statistically significant
difference in the frequency of defecation between the two agents
at eight weeks (mean 7 stools per week in the fibre group versus 6
stools per week in the lactulose group; P = 0.481).
Safety
The authors reported no serious or significant adverse effects.
There were three cases of diarrhoea (one in the fibre mixture group
and two in the lactulose group).
Senna versus Lactulose
One crossover study (Perkin 1977), compared sennawith lactulose
(21 participants),
Efficacy
Passage of stool
There was no statistically significant difference between the two
agents in the number of patients passing stools of any kind each
day.
Safety
No serious or significant adverse effects were reported in the two
study groups.Minor adverse events such as colic or diarrhoea, were
more commonly seen in the senna group.
Subgroup and sensitivity analyses
GIven the heterogenous nature of the included studies, further
subgroup or sensitivity analyses were not completed.
Publication Bias
Publication bias was not investigated as there were not enough
studies in any of the pooled analyses to construct a reliable funnel
plot.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
PEG versus lactulose for the management of childhood constipation
Patient or population: pat ients aged 0 to 18 years with a diagnosis of funct ional const ipat ion
Settings: outpat ient
Intervention: PEG versus lactulose
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control PEG versus lactulose
Frequency of defeca-
tion (mean number of
bowel movements per
week)
The mean number
of bowel movements
ranged across the lac-
tulose groups f rom 0.8
to 13.5 per week
The mean number of
bowel movements in
the PEG group was on
average 0.70 higher per
week (95% CI 0.10 to 1.
31)
465
(6 studies)
⊕©©©
very low1,2
Need for additional
therapies
3 13 per 1000 3 1 72 per 1000
( 113 to 26 0 )
RR 0.5 5
(0.3 6 to 0 .83 )
304
( 4 studies)
⊕⊕©©
low4,5
Successful
disimpaction
800 per 1000 6 9 92 per 1000
(8 08 to 1 000 )
RR 0.55
(0.36 to 0.83)
50
( 1 stud y )
⊕⊕©©
low7,8
Adverse events 4 54 per 1000 3 3 95 per 1000
(3 09 to 5 04 )
RR 0.8 7
(0.6 8 to 1 .11 )
242
(3 studies)
⊕⊕⊕©
m oderate 9
Serious adverse events 1 4 per 1000 3 3 3 per 1000
( 5 to 2 16 )
RR 2 .43
(0.3 7 to 1 5.96 )
145
(2 studies)
⊕⊕©©
low10
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval;
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded two levels due to serious Inconsistency (high stat ist ical heterogeneity I2 = 69%; P = 0.007).
2 Downgraded one level due to high risk of bias in two studies in the pooled analysis (i.e. lack of blinding and select ive
report ing).
3 Control group risk comes f rom control arm of meta-analysis, based on included trials.
4 Downgraded one level due to high risk of bias in one study in the pooled analysis (i.e. lack of blinding).
5 Downgraded one level due to sparse data (74 events).
6 Control group risk comes f rom control arm of the included study.
7 Downgraded one level due to high risk of bias (i.e. lack of blinding).
8 Downgraded one level due to sparse data (45 events).
9 Downgraded one level due to sparse data (100 events).
10 Downgraded two levels due to very sparse data (4 events).
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PEG versus milk of magnesia (M OM ) for the management of childhood constipation
Patient or population: pat ients aged 0 to 18 years with a diagnosis of funct ional const ipat ion
Settings: outpat ient
Intervention: PEG versus MOM
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control PEG versus M OM
Frequency of defeca-
tion (mean number of
bowel movements per
week)
The mean number
of bowel movements
ranged across the MOM
groups f rom 4.3 to 9.7
per week
The mean number of
bowel movements in
the PEG group was on
average 0.69 higher per
week (95% CI 0.48 to 0.
89)
211
(3 studies)
⊕⊕©©
low1,2
Successful
disimpaction
960 per 1000 3 9 98 per 1000
( 89 3 to 1 000 )
RR 1 .04
(0.9 3 to 1.16)
50
( 1 stud y )
⊕⊕©©
low4,5
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level due to sparse data (211 pat ients).
2 Downgraded one level due to high risk of bias in two studies in pooled analysis (i.e. lack of blinding in one study and lack of
blinding, incomplete outcome data and select ive report ing in the other study).
3 Control group risk comes f rom control arm of the included study.2
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4 Downgraded one level due to high risk of bias (i.e. lack of blinding).
5Downgraded one level due to sparse data (49 events).
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PEG versus enema for the management of childhood constipation
Patient or population: pat ients aged 0 to 18 years with a diagnosis of funct ional const ipat ion
Settings: outpat ient
Intervention: PEG versus enema
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control PEG versus enema
Frequency of defeca-
tion (mean number of
bowel movements per
week)
The mean number of
bowel movements in
the enema group was 7.
7 per week
The mean number of
bowel movements in
the PEG group was on
average 1.0 higher per
week (95% CI -1.58 to
3.58)
80
(1 study)
⊕⊕©©
low1,2
S uccessful disim-
paction
8 04 per 1000 3 6 84 per 1000
(5 31 to 8 77 )
RR 0 .85
(0.6 6 to 1 .51 )
90
(1 study)
⊕⊕©©
low2,4
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level due to sparse data (80 pat ients).
2 Downgraded one level due to high risk of bias (i.e. lack of blinding and select ive report ing).
3 Control group risk comes f rom control arm of the included study.
4Downgraded one level due to sparse data ( 67 pat ients).2
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PEG versus paraffin for the management of childhood constipation
Patient or population: pat ients aged 0 to 18 years with a diagnosis of funct ional const ipat ion
Settings: outpat ient
Intervention: PEG versus paraf f in
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control PEG versus paraffin
Frequency of defeca-
tion (mean number of
bowel movements per
week)
The mean number
of bowel movements
ranged across the
paraf f in groups f rom 4.
5 to 6.3 per week
The mean number of
bowel movements in
the PEG group was on
average 0.35 higher per
week (95% CI -0.24 to
0.95)
261
(2 studies)
⊕©©©
very low1,2
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level due to sparse data (261 pat ients).
2 Downgraded two levels due to high risk of bias in both studies (i.e. lack of blinding, incomplete outcome data and select ive
report ing).
2
4
O
sm
o
tic
a
n
d
stim
u
la
n
t
la
x
a
tiv
e
s
fo
r
th
e
m
a
n
a
g
e
m
e
n
t
o
f
c
h
ild
h
o
o
d
c
o
n
stip
a
tio
n
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
PEG versus flixweed for the management of childhood constipation
Patient or population: pat ients aged 0 to 18 years with a diagnosis of funct ional const ipat ion
Settings: outpat ient
Intervention: PEG versus f lixweed
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control PEG versus flixweed
Frequency of defeca-
tion (mean number of
bowel movements per
week)
The mean number of
bowel movements in
the f lixweed group was
5 per week
The mean number of
bowel movements in
the PEG group was on
average 0.00 higher per
week (95% CI -0.33 to
0.33)
109
(1 study)
⊕⊕©©
low1,2
Need for additional
therapies
5 4 per 1000 3 1 89 per 1000
(55 to 648)
RR 3 .52
(1.03 to 12.10)
109
(1 study)
⊕©©©
very low 2,4
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level due to sparse data (109 pat ients).
2 Downgraded one level due to high risk of bias (i.e. lack of blinding). Random sequence generat ion, allocat ion concealment
and incomplete outcome data were rated as unclear risk of bias.
3 Control group risk comes f rom control arm of the included study.2
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4 Downgraded two levels due to very sparse data (13 events).
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PEG versus dietary fibre for the management of childhood constipation
Patient or population: pat ients aged 0 to 18 years with a diagnosis of funct ional const ipat ion
Settings: outpat ient
Intervention: PEG versus dietary f ibre
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control PEG versus dietary fi-
bre
Frequency of defeca-
tion (mean number of
bowel movements per
week)
The mean number of
bowel movements in
the dietary f ibre group
was 5.6 per week
The mean number of
bowel movements in
the PEG group was on
average 0.20 higher per
week (95% CI -0.64 to
1.04)
83
(1 study)
⊕⊕©©
low1,2
Need for additional
therapies
4 0 per 1000 3 2 0 per 1000
(2 to 214)
RR 0 .50
(0.05 to 5.34)
100
(1 study)
⊕⊕©©
very low 2,4
Frequency of faecal in-
continence
The mean number
of faecal incont inence
episodes in the dietary
f ibre group was 0.3 per
week
The mean number
of faecal incont inence
episodes in the PEG
group was on average
-0.10 lower per week
(95% CI -0.62 to 0.42)
83
(1 study)
⊕⊕©©
low1,2
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval;
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level due to sparse data (83 pat ients).
2 Downgraded one level due to high risk of bias (i.e. lack of blinding). Random sequence generat ion, allocat ion concealment
and incomplete outcome data were rated as unclear risk of bias.
3 Control group risk comes f rom control arm of the included study.
4 Downgraded two levels due to very sparse data (3 events).
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High dose PEG versus low dose PEG for the management of childhood constipation
Patient or population: pat ients aged 0 to 18 years with a diagnosis of funct ional const ipat ion
Settings: outpat ient
Intervention: High dose PEG versus low dose PEG
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control High dose PEG versus
low dose PEG
Frequency of defeca-
tion (mean number of
bowel movements per
week)
The mean number of
bowel movements in
the low dose PEG group
was 5.2 per week
The mean number of
bowel movements in
the high dose PEG
group was on average
1.3 higher per week
(95% CI 0.76 to 1.84)
90
(1 study)
⊕⊕©©
low1,2
Need for additional
therapy
3 70 per 1000 3 1 81 per 1000
(89 to 377)
RR 0 .49
(0. 24 to 1 .02)
90
(1 study)
⊕©©©
very low 2,4
Faecal incontinence 130 per 10003 22 per 1000
(3 to 181)
RR 0.17
(0.02 to 1.39)
90
(1 study)
⊕©©©
very low2,5
Adverse events 65 per 1000 3 9 1 per 1000
(2 2 to 3 83 )
RR 1 .39
(0.3 3 to 5 .88 )
90
(1 study)
⊕©©©
very low2,5
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval;
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level due to sparse data (90 pat ients).
2 Downgraded one level due to high risk of bias (i.e. lack of blinding).
3 Control group risk comes f rom control arm of the included study.
4 Downgraded two levels due to very sparse data (25 events).
5 Downgraded two levels due to very sparse data (7 events).
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Liquid paraf f in (m ineral oil) versus lactulose for the management of childhood const ipat ion
Patient or population: pat ients aged 0 to 18 years with a diagnosis of funct ional const ipat ion
Settings: outpat ient
Intervention: Liquid paraf f in (m ineral oil) versus lactulose
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control PEG versus lactulose
Frequency of defeca-
tion (mean number of
bowel movements per
week)
The mean number
of bowel movements
ranged across the lac-
tulose groups f rom 8.1
to 12.3 per week
The mean number of
bowel movements in
the PEG group was on
average 4.94 higher per
week (95% CI 4.28 to 5.
61)
287
(2 studies)
⊕⊕©©
low1,2
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level due to sparse data (287 pat ients).
2 Downgraded one l evel due to high risk of bias in two studies in pooled analysis (i.e. lack of blinding ).
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Lactulose versus lact itol f or the management of childhood const ipat ion
Patient or population: pat ients aged 0 to 18 years with a diagnosis of funct ional const ipat ion
Settings: outpat ient
Intervention: Lactulose versus lact itol
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Lactulose versus lacti-
tol
Frequency of defeca-
tion (mean number of
bowel movements per
week)
The mean number of
bowel movements in
the lact itol group was
5.6 per week
The mean number of
bowel movements in
the lactulose group was
on average 0.8 lower
per week (95% CI -2.63
to 1.03)
42
(1 study)
⊕⊕©©
low1,2
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level due to sparse data (42 pat ients).
2 Downgraded one level due to high risk of bias (i.e. select ive report ing). Random sequence generat ion, allocat ion concealment
and blinding were rated as unclear risk of bias.
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Lactulose versus milk of magnesia (MOM) for the management of childhood const ipat ion
Patient or population: pat ients aged 0 to 18 years with a diagnosis of funct ional const ipat ion
Settings: outpat ient
Intervention: Lactulose versus milk of magnesia (MOM)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Lactulose versus M OM
Frequency of defeca-
tion (mean number of
bowel movements per
week)
The mean number of
bowel movements in
the MOM group was 4.
7 per week
The mean number of
bowel movements in
the lactulose group was
on average 1.51 lower
per week (95% CI -2.63
to -0.39)
50
(1 study)
⊕⊕©©
low1,2
Successful
disimpaction
960 per 10003 797 per 1000
(643 to 989)
RR 0.83
(0.67 to 1.03)
50
(1 study)
⊕⊕©©
low2,4
Need for additional
therapies
200 per 10003 400 per 1000
(160 to 1000)
RR 2.00
(0.80 to 5.02)
50
(1 study)
⊕©©©
very low2,5
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level due to sparse data (50 pat ients).3
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2 Downgraded one level due to high risk of bias (i.e. lack of blinding). Allocat ion concealment and incomplete outcome data
were rated as unclear risk of bias.
3 Control group risk comes f rom control arm of the included study.
4 Downgraded one level due to sparse data (44 pat ients).
5 Downgraded two levels due to very sparse data (15 pat ients).
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Lactulose versus part ially hydrolyzed guar gum (PHGG) for the management of childhood const ipat ion
Patient or population: pat ients aged 0 to 18 years with a diagnosis of funct ional const ipat ion
Settings: outpat ient
Intervention: Lactulose versus part ially hydrolyzed guar gum (PHGG)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Lactulose versus PHGG
Frequency of defeca-
tion (mean number of
bowel movements per
week)
The mean number of
bowel movements in
the PHGG group was 5.
0 per week
The mean number of
bowel movements in
the lactulose group was
on average 1.0 higher
per week (95% CI -1.80
to 3.80)
61
(1 study)
⊕⊕©©
low1,2
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level due to sparse data (61 pat ients).
2 Downgraded one level due to unclear risk of bias (i.e. random sequence generat ion, allocat ion concealment, blinding and
select ive report ing were rated as unclear risk of bias).
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D I S C U S S I O N
Summary of main results
Lactulose was compared to liquid paraffin (Urganci 2005;
Farahmand 2007), lactitol (Pitzalis 1995), milk of magnesia
(Saneian 2012) , dietary fibre (Kokke 2008), and partially hy-
drolyzed guar gum (Ustundag 2010) and senna (Perkin 1977).
Despite the many agents that it was compared to, no trial found
superiority of lactulose in terms of efficacy. Lactulose was found
to be inferior to liquid paraffin and milk of magnesia. There were
no studies comparing lactulose to placebo. In addition, the occur-
rence of minor adverse events, such abdominal cramps and flatus,
were more common in the lactulose groups.
PEG was frequently studied, with trials comparing its efficacy for
constipation with lactulose (Gremse 2002; Voskujl 2004; Dupont
2005; Candy 2006; Wang 2007; Saneian 2012; Treepongkaruna
2014), milk of magnesia (Loening-Baucke 2006; Ratanamongkol
2009; Gomes 2011; Saneian 2012), enema (Bekkali 2009) , liq-
uid paraffin (Tolia 1993; Karami 2009; Rafati 2011), flixweed
(Nimrouzi 2015), dietary fibre (Quitadamo 2012) and placebo
(Thomson 2007; Nurko 2008). Dziechciarz 2015 compared high
dose PEG (0.7 g/kg) to low dose PEG (0.3 g/kg). PEG was found
to be superior to placebo, lactulose, and milk of magnesia. How-
ever, the effect size was modest in these analyses, particularly for
the pooled analysis of PEG versus milk of magnesia and PEG ver-
sus lactulose. Although PEG was superior to milk of magnesia
and lactulose the magnitude of this difference was quite small and
may not be clinically significant. One study (N = 90) found high
dose PEG (0.7 g/kg) to be superior to low dose PEG (0.3 g/kg)
(Dziechciarz 2015). With the exception of one case of allergy to
PEG, no significant adverse events were associated with the use of
PEG and the limited evidence reported suggests that minor ad-
verse events occur with a similar or reduced frequency.
A pooled analysis of two studies (n = 261 participants) found no
difference in efficacy between PEG and liquid paraffin. One study
(n = 80) found no difference between PEG and rectal enemas in
efficacy for treating faecal impaction. Nimrouzi 2015 found no
difference in efficacy between PEG and flixweed and Quitadamo
2012 found no difference between PEG and dietary fibre. How-
ever, no firm conclusions regarding efficacy can be drawn from
these studies. None of these studies were designed to be formal
equivalence of non-inferiority studies.
The largest treatment effect in terms of the frequency of defecation
(i.e. number of stools per week), was seen with liquid paraffin
(mineral oil) when compared to lactulose. While a number of case
reports have been made that raise safety concerns about liquid
paraffin in terms of the risk of aspiration pneumonia (Zanetti
2007), no cases of liquid paraffin-related pneumoniawere reported
in the trials in this review.
Overall completeness and applicability of
evidence
While there are a large number of studies included in this review,
it is clear that these studies are extremely heterogenous, with nine
different study agents and a variety of specific treatment regimens
reported. As such, despite the common nature of the problem,
it is difficult to draw particularly strong conclusions for any of
the investigated agents. The scope of this study was osmotic and
stimulant laxatives, but the vast majority of studies investigated
osmotic laxatives.
If we consider PEG, while this was the most studied agent in
19 different trials, with a total of 1757participants, these stud-
ies compared PEG to seven different agents, as well as its use for
constipation or faecal impaction. However, there was wide vari-
ation in study length and the time at which outcomes were as-
sessed. Clearly, given themodest effect sizes and small sample sizes,
coupled with these variations in treatment protocols (i.e. time of
outcome assessment, use of additional therapies, specific form of
interventional laxative used), the ability to use these findings to
inform clinical practice is modest at best. These factors have cer-
tainly contributed to the statistical evidence of heterogeneity in
intervention effects observed in meta-analyses comparing PEG to
placebo or lactulose.
As constipation is a chronic problem, outcomes really need to be
assessed in the medium to long term. However, only one study as-
sessed outcomes beyond three months and half of the studies mea-
sured outcomes at one month or less. If management of chronic
constipation is considered in terms of induction (disimpaction)
and maintenance of remission, the limitation in the application
of these results becomes apparent. It is difficult to comment on
the ability of PEG or lactulose to maintain a child’s normal bowel
habits over the long term, when the studies have such short follow-
up periods. In addition, outcomes such as frequency of defecation
are inherently limited in relation to the realities of clinical practice.
While there may be a statistically significant increase in rates of
defecation between study groups, this does not give any informa-
tion as to whether the patient or their parents feel that there has
been a functional improvement.
Quality of the evidence
There were no studies that were judged to be fully free of risk of
bias. While the majority of studies described themselves as ran-
domised, only 10 studies provided enough detail to be judged as
low risk of bias. The other studies were rated as unclear for random
sequence generation. This was also the case for allocation conceal-
ment, again with the majority of studies giving insufficient detail
to be judged as low risk of bias. Ten studies were open label (high
risk of bias) or reported insufficient information to be judged as
low risk of bias for blinding. Three studies were judged to be at
high risk of bias for incomplete outcome data and five studies were
36Osmotic and stimulant laxatives for the management of childhood constipation (Review)
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judged to be at high risk of bias due to selective reporting. This
has to be considered when judging the conclusions of this review.
Furthermore, GRADE analyses indicated that the overall quality
of the evidence for the primary outcome (number of stools per
week) was low or very low due to sparse data, inconsistency (het-
erogeneity), and high risk of bias in the studies in the pooled anal-
yses. Thus, given these concerns the results of the pooled analyses
should be interpreted with caution.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence base suggests that PEG is moderately effective at
improving the frequency of defecation in children with chronic
constipation when compared to placebo and more effective than
other agents, such as lactulose, milk of magnesia or liquid paraffin
(mineral oil). It also appears to have a good safety profile, with
minor adverse events common, but less so than with these other
agents. Evidence from one study suggests that high dose PEG (0.7
g/kg) may be more effective than low dose PEG (0.3 g/kg). The
strength of the evidence base is limited by sparse data, inconsis-
tency (clinical and statistical heterogeneity) and a high risk of bias
in some studies included in the pooled analyses. It is also difficult
to comment on the use of PEG for the long term management of
childhood constipation as most studies only measured short term
outcomes. While only two studies investigated liquid paraffin in
comparison with lactulose, they found a reasonable effect size sup-
porting the use of liquid paraffin. There was no evidence found to
suggest lactulose is more effective than the other agents studied,
but there was a lack of placebo controlled trials.
Implications for research
The evidence base for this extremely prevalent problem is small
and published papers are generally of sub-optimal quality, as well
as having problems with methodological, statistical and clinical
heterogeneity. As such, the strength of our conclusions is extremely
limited and more research is needed. Key questions that need ad-
dressing include the safety of liquid paraffin, given its apparent ef-
fectiveness, but limited investigation. In particular, future research
should compare liquid paraffin to PEG. The optimal dose of PEG
warrants further investigation. The role of PEG for the long term
management of chronic constipation also needs further investi-
gation to allow research to better inform actual clinical practice.
There is a lack of studies comparing lactulose with placebo.
Future research should be clear at the outset as to whether it seeks
to investigate the use of agents for the induction of remission from
severe constipation, or whether it will investigate maintenance of
normal bowel habits. Studies should be reported in sufficient detail
to allow the methodology to be assessed and replicated by other
researchers.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bekkali 2009
Methods Randomised controlled open label trial PEG + electrolytes versus enemas for faecal
impaction
Participants 90 children between 4 and 16 years of age and demonstrated evidence of faecal impaction
on rectal examination
Participants had to fulfil > 1 Rome III criteria for functional constipation present for 8
weeks:
(1) defecation frequency of 3 times per week
(2) > 1 faecal incontinence episode per week
(3) history of retentive posturing or excessive volitional stool retention
(4) history of painful or hard defecation
(5) history of large-diameter stools that may obstruct the toilet
Patients with a history of colorectal surgery or an organic cause for constipation were
excluded
Interventions Peg 3350 + electrolytes (Movicolon, Norgine, Amsterdam) 1.5 g/kg per day for 6 con-
secutive days - then maintenance (0.5 g/kg per day) for 2 weeks
Dioctylsulfosuccinate sodium enemas (Klyx, Pharmachemie, Haarlem, The Nether-
lands)
Once daily for 6 consecutive days (60 mL for children < 6 years of age and 120 mL for
children > 6 years of age)
Outcomes The primary outcome was successful disimpaction. Secondary outcome measures of
defecation and faecal incontinence frequency, abdominal pain, watery stools, CTT val-
ues, and child’s behavior scores were calculated for children who completed the study
protocol Follow-up for 2 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Open label
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-outs were balanced across treatment
groups with similar reasons for withdrawal
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Bekkali 2009 (Continued)
Selective reporting (reporting bias) High risk No adverse event data reported
Other bias Low risk None apparent
Candy 2006
Methods Open label treatment of faecal impaction with PEG + electrolytes followed by a ran-
domised double blind controlled trial of PEG + electrolytes versus lactulose
Only data from second phase of the trial were analysed
Participants Children aged 2 to 11 years could be enrolled in the study if they had intractable
constipation that had failed to respond to conventional treatment and would require
hospital admission for disimpaction
58 children were enrolled
All patients included had successfully been disimpacted in phase 1 of the trial
Children were excluded if they had any condition contraindicating the use of PEG + E
or lactulose or pre-existing organic pathology
Interventions PEG3350 + electrolytes (Movicol, Norgine, UK) 1 sachet per day (mean) versus lactulose
(10 g lactulose powder dissolved in at least 125 mL water), 2.5 sachets per day (mean)
Concomitant use of senna allowed
Outcomes The primary outcome was the mean number of defecations per week. Secondary out-
comes included amount of stool, problems on defecation (pain, straining, abdominal
pain, rectal bleeding or soiling). Follow-up for 12 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study sponsor contacted and confirmed
they generated a computerised randomisa-
tion list
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Similar appearance of products, identical
packaging
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of the 10 children (17%) who did not
complete phase 2, seven withdrew whilst
taking lactulose because re-impaction oc-
curred, two (from the lactulose group) did
not want to continue and one (from the
PEG + E group) did not complete the diary
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Candy 2006 (Continued)
card
Selective reporting (reporting bias) Low risk Data reported appropriately
Other bias Low risk None apparent
Dupont 2005
Methods Randomised double blind controlled trial of PEG 4000 versus lactulose
Participants 96 children aged6months to 3 yearswith constipation despite the usual dietary treatment
for at least 1 month
Children were ineligible if they had a history of intractable fecaloma or organic gastroin-
testinal disease such as Hirschsprung disease
Interventions PEG 4000 1 sachet (4 g/sachet) versus Lactulose 1 sachet /(3.33grames/sachet) - the
dose could be doubled if ineffective
If the maximum authorized dose was unsuccessful, one micro-enema (glycerol) per day
could be prescribed for a maximum of 3 consecutive days
If the child produced no stools after treatment two enemas could be administered at a
48-hour interval
Outcomes The primary endpoint was biological tolerance
Secondary endpoints included clinical efficacy measured by stool frequency and consis-
tency, disappearance of abdominal pain and bloating
Follow-up was up to 12 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Described and appropriate
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-outs were balanced across treatment
groups with similar reasons for withdrawal
Selective reporting (reporting bias) Low risk Data reported appropriately
Other bias Low risk None apparent
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Dziechciarz 2015
Methods Randomised open-label trial comparing high dose to low dose PEG 4000
Participants 92 children 1 to 18 years of age with functional constipation defined according to the
Rome III criteria
Children with a diagnosis of irritable bowel syndrome, mental retardation, endocrine
disease, an organic cause of defecation disorders, functional non-retentive fecal inconti-
nence, or intake of medications influencing gastrointestinal motility were excluded
Interventions PEG 4000 0.7 g/kg (Forlax) for 6 weeks (n = 45)
PEG 4000 0.3 g/kg for 6 weeks (n = 47)
Outcomes Primary outcome: treatment success, defined as 3 or more bowel movements per week
with no fecal soiling during the last week of the intervention
Secondary outcomes: need for therapy adjustment, the number of stools perweek, painful
defecation, abdominal pain, fecal incontinence, parental satisfaction treatment (10-cm
visual analog scale during the final visit), adverse events and compliance
Assessment of outcome measures was based on the diaries collected during the final visit
Compliance was assessed during telephone contacts every 2 weeks and at the final visit
at week 6
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation, with a block size of 4,
was done with a computer-generated ran-
dom number list prepared by an investiga-
tor with no clinical involvement in the trial
Allocation concealment (selection bias) Low risk Centralized randomisation conducted by
an by an investigator with no clinical in-
volvement in the trial
The list was concealed from the clinicians
enrolling patients and assessing outcomes,
as well as from the parents, until the end of
the study
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label study
Incomplete outcome data (attrition bias)
All outcomes
Low risk One child in the high-dose group and 1
child in the low-dose group discontinued
the study and were lost to follow-up
Selective reporting (reporting bias) Low risk Data reported appropriately
45Osmotic and stimulant laxatives for the management of childhood constipation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dziechciarz 2015 (Continued)
Other bias Low risk None apparent
Farahmand 2007
Methods Randomised controlled open label trial comparing liquid paraffin versus lactulose
Participants 247 children aged 1 month to 12 years with diagnosis of functional constipation
Children with organic causes for defecation disorders were excluded from the study
Interventions Liquid paraffin or lactulose, 1-2 ml/kg twice daily for each drug, for 8 weeks, increase
or decrease of volume of each drug allowed by 25% every 3 days as required, to yield, 1
or 2, firm to loose stools
Patients received one or two enemas daily for two days to clear any rectal impaction at
study entry
Outcomes Primary outcome was the number of successful bowel movements per week, with treat-
ment success defined as three or more episodes per week
Secondary outcomes were the incidence and severity of adverse events
Follow-up was for 8 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Open label
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-outs were balanced across treatment
groups with similar reasons for withdrawal
Selective reporting (reporting bias) Low risk Data reported appropriately
Other bias Low risk None apparent
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Gomes 2011
Methods Randomised controlled open label trial comparing PEG to magnesium hydroxide
Participants 38 children aged 1 to 15 years old with functional constipation according to the Rome
III criteria
Children with excluded organic causes, neurological problems or previous surgery to the
digestive system were excluded
Interventions 1 mL/kg/day for magnesium hydroxide (maximum dose 3 mL/kg/day, up to 60 mL/
day) and 0.5 g/kg/day for PEG (maximum dose 1.5 g/kg/day, up to 48 g/day)
Outcomes Outcomes included: Stool characteristics (Bristol), frequency of bowelmovements (num-
ber of movements per week), abdominal pain, straining, faecal incontinence, and accep-
tance of medication
Therapeutic interventions were considered failures when there was lack of acceptance,
vomiting upon administration or absence of improvement in frequency of bowel move-
ments and/or ongoing Bristol types 1, 2 or with use of maximum doses of themedication
from the moment of the first return appointment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Open label
Incomplete outcome data (attrition bias)
All outcomes
High risk No details regarding dropouts reported
Selective reporting (reporting bias) High risk No details regarding adverse events re-
ported
Other bias Low risk None apparent
Gremse 2002
Methods Randomised controlled open label crossover trial of PEG versus lactulose
Participants 37 children aged 2 to 16 years of age who were referred for subspecialty evaluation of
constipation completed the study
Children with organic disease were excluded
47Osmotic and stimulant laxatives for the management of childhood constipation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gremse 2002 (Continued)
Interventions PEG3350 (Miralax, Braintree Laboratories, Inc, Braintree,MA) 10 g/m2 /day or lactulose
1.3 g/kg/day both for two weeks and then patients switched agents for a further two
weeks
Outcomes Primary outcome was number of defecations per week
Secondary outcomes included stool form, ease of passage and global assessments by
parents
4 week follow-up
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Open label
Incomplete outcome data (attrition bias)
All outcomes
Low risk Seven patients withdrew during the first 2-
week treatment period due to lack of effi-
cacy of the assigned stool softener.
Six of the patients were taking lactulose at
the time ofwithdrawal, while the other sub-
ject was taking PEG 3350
Selective reporting (reporting bias) High risk Details not reported - no response from au-
thor
Other bias Low risk None apparent
Karami 2009
Methods Randomised, single-blind trial comparing PEG to liquid paraffin
Participants 126 functionally constipated children aged 1 to 15 years
Children with organic constipation, anorectal abnormalities, or a history of anorectal
surgery were excluded
Interventions PEG 40% solution without electrolytes at an average dose of 1 cc/kg (equal to 0.8 g/kg)
. twice a day for one month (n = 48)
Liquid paraffin at an average dose of 1 cc/kg was given twice daily for one month (n =
55)
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Karami 2009 (Continued)
Outcomes Stool frequency per week, painful defecation, blood-stained stools, stool consistency and
number of encopresis occurrences per month
Therapeutic response (sum of above outcomes) was scored as follows: poor (6-10), mod-
erate (11-15) and good (16-21)
Patients were followed up every week for one month, thereafter monthly for 2 to 4
months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Single-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk 23 children did not complete the study,
it is unclear to which group these chil-
drenwere randomised and reasons forwith-
drawal were not described
Selective reporting (reporting bias) Low risk Data appear to be reported appropriately
The authors report that there were no side
effects in the discussion section
Other bias Low risk None apparent
Kokke 2008
Methods Randomised double blind controlled trial of a dietary fibre mix versus lactulose
Participants 135 children ages 1 to 13 years were included
Children with organic causes of defecation disorders were excluded
Interventions Patients received either a yogurt drink containing lactulose (10 g/125 mL, Duphalac
Lactulose, Solvay, the Netherlands).or a mixed dietary fibre (10 g/125 mL)
The fibre mixture yogurt contained 3.0 g transgalacto-oligosaccharides (Vivinal GOS
Elixor Sirup, Friesland Foods Domo, Zwolle, the Netherlands), 3.0 g inulin (Frutafit
TEX, Cosun, Roosendaal, theNetherlands), 1.6 g soy fibre (Fibrim 2000, J. Rettenmaier
& Sohne, Ellwangen, Germany), and 0.33 g resistant starch 3 (Novelose 330, National
Starch&Chemical GmbH, Neustadt, Germany) per 100 mL
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Kokke 2008 (Continued)
Outcomes The primary outcome parameter was defecation frequency per week
Secondary outcome parameters included faecal incontinence each day stool consistency
and flatulence
Follow-up was for 12 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated list
Allocation concealment (selection bias) Low risk Sequence allocation coordinated by exter-
nal research organisation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Bottles with yogurt were prepared and
packed byNumico Research (Wageningen,
the Netherlands)
Storage and delivery were supervised by the
local hospital pharmacist
The treatment products could not be dis-
tinguished from each other with respect to
colour, taste, or consistency
Incomplete outcome data (attrition bias)
All outcomes
Low risk 22 participants in the fibre group dropped
out compared to 11 participants in the lac-
tulose group
Selective reporting (reporting bias) Low risk Data reported appropriately
Other bias Low risk None apparent
Loening-Baucke 2006
Methods Randomised controlled open label trial comparing PEG 3350 without electrolytes with
milk of magnesia
Participants 79 children aged > 4 years and presence of functional constipation with faecal inconti-
nence
Exclusion criteria included organic causes for symptoms, toileting refusal or medication
refusal
Interventions PEG 0.7 g/kg body weight daily or milk of magnesia 2 mL/kg body weight daily
Instructions were given to parents on how to vary doses to achieve acceptable stools
Children were disimpacted with 1 or 2 phosphate enemas in the clinic on the day of the
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Loening-Baucke 2006 (Continued)
visit, if necessary, and started laxative therapy that evening
Senna was allowed
Outcomes Primary outcome was Improvement defined as 3 bowel movements per week, 2 episodes
of faecal incontinence per month, and no abdominal pain, with or without laxative
therapy
Secondary outcomes included (1) improvement in stool frequency per week, improve-
ment in episodes of faecal incontinence per week, and resolution of abdominal pain; (2)
safety profile; and (3) patient’s acceptance and compliance
Follow-up was for 12 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Drawing lots
Allocation concealment (selection bias) Low risk Assignments in sealed envelopes
Blinding (performance bias and detection
bias)
All outcomes
High risk Open label
Incomplete outcome data (attrition bias)
All outcomes
Low risk 19 patients dropped out of themilk ofmag-
nesia group compared to 5 patients in the
PEG group
Selective reporting (reporting bias) Low risk Data reported appropriately
Other bias Low risk None apparent
Nimrouzi 2015
Methods Randomised open label trial comparing PEG to flixweed (Descurainia sophia L.) (D.
sophia)
Participants 120 children aged 2 - 12 years old who met the Rome III criteria were enrolled in the
study
Children with organic causes of constipation including Hirschsprung’s disease, spina bi-
fida occulta, hypothyroidism, cystic fibrosis, neurologic abnormalities, intestinal pseudo-
obstruction, and diabetes mellitus were excluded
Interventions PEG (40% solution without electrolytes) at a dose of 0.4 g/kg for 8 weeks (n = 53)
Flixweed at a dose of 2 g/day for children 2 - 4 years old and 3 g/day for children 4 - 12
years old patients taken once daily for 8 weeks (n = 56)
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Nimrouzi 2015 (Continued)
Outcomes Primary outcome: proportion of patients who responded to treatment, defined as im-
provement of constipation (at least three bowel movements per week), soft stool and
convenient defecation, no soiling or bloody stool as well as exiting the Rome III criteria
for constipation after the third week
Secondary outcomes: stool frequency, abdominal pain, drug compliance, hard stool
frequency, painful defecation, retention, soiling, blood stained stool, adverse events, need
for additional therapy
The efficacy of the intervention in both groups was evaluated at three weeks and eight
weeks of follow-up
Notes Patients were withdrawn from the study if they had no bowel movement for seven days
or developed fecal impaction
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Block randomisation: method not de-
scribed
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Open label
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 11 patients withdrew consent during the
first week of treatment, the authors do not
report to which group these patients were
randomised
Selective reporting (reporting bias) Low risk Data reported appropriately
Other bias Low risk None apparent
Nurko 2008
Methods Randomised, multicenter, double-blind trial comparing PEG 3350 with placebo
Participants 103 children 4 to 16 years of age
Patients who were taking other laxatives were included only if they had > 3 bowel
movements per week while taking the laxative, and all laxatives were stopped at least 2
days before the run-in period started
Exclusion criteria included children with organic causes of constipation
Interventions PEG3350, (MiraLax, Braintree Laboratories, Inc; Braintree, MA) at doses of 0.2, 0.4,
0.6 or 0.8 grams per kilogram per day or placebo. (CrystalLight, Proctor and Gamble;
Cincinnati, OH)
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Nurko 2008 (Continued)
All participants received behavioural modification
Outcomes The primary outcome was the proportion of patients who responded to treatment -
response to treatment was defined as > 3 bowel movements during the second week of
treatment
Secondary efficacy variables included the weekly number of BM and faecal incontinence
episodes and changes in the scores of stool consistency, straining, and abdominal cramp-
ing
2 weeks follow-up
Notes Additional Mean and Standard deviation data regarding the frequency of defecations
were obtained from Braintree Labs Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Identically labelled bottles that were recon-
stituted with water to 4,000 mL by study
personnel in the pharmacy. There was no
difference in the colour, appearance, or
taste among the different doses
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-outs were balanced across treatment
groups with similar reasons for withdrawal
Selective reporting (reporting bias) Low risk Data reported appropriately
Other bias Low risk None apparent
Perkin 1977
Methods Randomised controlled crossover trial of lactulose versus senna
Participants 21 children under 15 years of age with a history of greater than 3 weeks constipation
Children with organic causes of constipation were excluded
Interventions Lactulose 10-15 mL per day or Senna 10-20 mL per day for 1 week, then1 week with
no treatment and then patients switched to received the other treatment
Outcomes Stool consistency, number of stools per day and adverse events
Follow-up for 3 weeks
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Perkin 1977 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random number list, but method of cre-
ation not described
Allocation concealment (selection bias) Low risk Assignments in sealed envelopes
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Although author describes that identical
bottles with no identification were used,
further detail to confirm blinding are not
given
Incomplete outcome data (attrition bias)
All outcomes
Low risk One participant from the senna group was
lost to follow-up
Selective reporting (reporting bias) Low risk Data reported appropriately
Other bias Low risk None apparent
Pitzalis 1995
Methods Randomised controlled trial comparing lactitol with lactulose
Participants 42 children aged 8 months - 16 years old with less than 3.5 stools per week
Patients with other organic pathology were excluded
Interventions Lacitol (Portolac zyma) 250 mg/kg/day single dose, could be increased to 400 mg/kg/
day
Lactulose (Epalfen zambon) 500 mg/kg/day single dose, could be increased to 750 mg/
kg/day
Outcomes Primary outcome measure was the frequency of defecation and secondary measures
included palatability and colonic transit time
Follow-up was for 1 month
Notes Italian publication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
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Pitzalis 1995 (Continued)
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk 9 children did not complete the study
Selective reporting (reporting bias) High risk No adverse events mentioned
Other bias Low risk None apparent
Quitadamo 2012
Methods Randomised, open label trial comparing PEG 3350 with electrolytes to a dietary fibre
mix consisting of acacia, psyllium and fructose
Participants 100 children diagnosed with chronic functional constipation as defined by the Rome III
criteria were enrolled in the study
Children with organic causes for constipation including Hirschsprung disease, spinal
bifida (occulta), hypothyroidism or other metabolic or renal abnormalities, mental re-
tardation, and children using lactulose or other laxatives, prebiotics or probiotics, in 4
weeks before the first visit were excluded
Interventions PEG 3350 at a dose of 0.5 g/kg per day (dose escalation up to 1 g/kg/day allowed for
children who did not improve after 3 days) for 8 weeks (n = 50)
Dietary fibre mix at a dose of 16.8 g/day (dose escalation up to 22.4 g/day allowed for
children who did not improve after 3 days) for 8 weeks (n = 50)
Outcomes Primary outcome: improvement of constipation, defined as: > 3 bowel movements per
week, > 2 stool consistency grade on Bristol Stool Form Scale, absence of fecal inconti-
nence, abdominal pain, pain on defecation, and fecal bleeding
Secondary outcomes: nausea, vomiting, and flatulence, safety profile, and patient’s ac-
ceptance and compliance
Follow-up occurred at 1, 2, 4, and 8 weeks after entry
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Childrenwere then randomly assigned into
2 groups according to an automatically gen-
erated randomisation list
How the list was generated was not de-
scribed
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Quitadamo 2012 (Continued)
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Open label
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 14 children dropped out from the dietary
mix fibre group (all due to bad taste) com-
pared to 3 children in the PEG 3350 group
( 2 due to bad taste and 1 lost to follow-up)
Selective reporting (reporting bias) Low risk Data reported appropriately
Other bias Low risk None apparent
Rafati 2011
Methods Randomised controlled trial comparing PEG with liquid paraffin
Participants 158 children aged 2 to 12 years with a history of functional constipation
Interventions 1.0-1.5 g/kg/day PEG 3350 or 1.0-1.5 ml/kg/day liquid paraffin orally for 4 months
PEG 3350 powder was prepared as a 40% solution to trust reliable to apply the paediatric
dosing and to increase compliance and liquid paraffin was provided from a pharmaceu-
tical factory
For rectal disimpaction, bisacodyl suppositories were applied at the beginning of the
study
Outcomes Primary outcomes were stool and encopresis frequency per week
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropouts are not explained
56Osmotic and stimulant laxatives for the management of childhood constipation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rafati 2011 (Continued)
Selective reporting (reporting bias) High risk No adverse event data reported
Other bias Low risk None apparent
Ratanamongkol 2009
Methods Randomised controlled trial comparing PEG 4000 without electrolytes to milk of mag-
nesia
Participants 94 infants and children aged one-four years
Patients with organic causes for their constipation or renal insufficiency were excluded
Interventions PEG 4000 without electrolytes, 0.5 g/kg/day, maximal does 1 g/kg/day or milk of mag-
nesia suspension, 400 mg/5mL, 0.5 mL/kg/day, maximal does 3 mL/kg/day
Outcomes The primary outcome measure was the improvement rate, defined as the proportion of
patients who had > three bowel movements per week, < two episodes of faecal inconti-
nence per month, and no painful defecation, with or without laxative therapy
Secondary outcomes included: 1) improvement in stool frequency per week; 2) the
proportion of the patients who had any adverse effects; and 3) the compliance rate,
defined as the proportion of patients who received more than 80% of the medication
Follow-up was for 4 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated random number list
Allocation concealment (selection bias) Low risk Sealed opaque assignment envelopes se-
quentially opened
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not clear whether this was a blinded study
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was one drop out in the PEG group
compared to four in the milk of magnesia
group
Selective reporting (reporting bias) Low risk Data reported appropriately
Other bias Low risk None apparent
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Saneian 2012
Methods Randomised controlled trial comparing PEG magnesium hydroxide, and lactulose
Participants 75 children aged 1 to 6-years with functional chronic constipation
Those with organic pathology were excluded
Interventions Lactose (Tolid Daroo, Tehran, Iran) 1 cc/kg/day for one month (n = 25) - dose could be
increased up to 3 cc/kg/day
Magnesium hydroxide (Tolid Daroo, Tehran, Iran) 1 cc /kg/day for one month (n = 25)
- dose could be increased up to 3 cc/kg/day
PEGwith no electrolyte 40%(School of Pharmacy, ShirazUniversity ofMedical Sciences,
Shiraz, Iran) 1 cc /kg/day for one month (n = 25) - dose could be increased up to 3 cc/
kg/day
Outcomes Therapeutic result defined as defecation equal to or more than 3 times per week without
pain and bleeding and fecal incontinence less than twice a month at the end of one
month treatment
Stool frequency per week, disimpaction, need to change therapy, adverse events, parent
and patient satisfaction
Follow-up occurred one week after end of treatment and once per month for 4 to 6
months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomisation: the
sample size calculated 75 subjects divided
in three 25-subject groups by systematic
randomisation using the randomisation
software
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding was not described
However, none of the patients received
placebo
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selective reporting (reporting bias) Low risk Data reported appropriately
Other bias Low risk None apparent
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Thomson 2007
Methods Randomised controlled double blind crossover trial comparing PEG 3350 with elec-
trolytes versus placebo
Participants 51 children aged 24 months to 11 years were eligible for enrolment
Constipation was defined according to the Rome criteria
Children were excluded from the study if they had current or previous faecal impaction
or organic pathology causing their constipation Also, if they were currently receiving
doses of stimulant laxatives considered by local observers to be at the higher end of their
own dose spectrum (senna or sodium picosulphate) with no effect, having assessed to
their clinical satisfaction adequate compliance
Interventions Placebo or PEG 3350 with electrolytes (Movicol, Norgine Pharnaceuticals, UK)]
The dosing regimen was based on age and clinical response
Participants received 2 weeks of therapy, followed by a 2 week washout period and then
a further 2 weeks with the alternate therapy
Outcomes The primary efficacy variable was the mean number of complete defecations per week
Secondary efficacy variables included the total number of complete and incomplete
defecations per week, pain on defecation, straining on defecation, faecal incontinence,
stool consistency, and a global assessment of treatment by the investigator and by the
child or his or her parent or guardian, as well as recording of adverse events
Follow-up for 6 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated random number list
Allocation concealment (selection bias) Low risk Sealed opaque envelopes used
Blinding (performance bias and detection
bias)
All outcomes
Low risk Described and appropriate
Incomplete outcome data (attrition bias)
All outcomes
Low risk Two participants dropped out of each
group
Selective reporting (reporting bias) Low risk Data reported appropriately
Other bias Low risk None apparent
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Tolia 1993
Methods Randomised controlled open trial comparingPEG3350withmineral oil (liquid paraffin)
for the treatment of faecal impaction
Participants 36 children older than 2 years in age with constipation were potentially acceptable for
the study
Patients were excluded if they had any other organic cause for their impaction. physical
examination by the presence of firm to hard faecal impaction in the anal canal and rectal
ampulla on an otherwise normal complete initial physical examination
Interventions PEG 3350 (Colyte, 20 mL/kg/hour for 4 hours) on two days or 30 mL/10kg of mineral
oil twice a day for two days
Those receiving PEG had a single dose of metoclopramide
Outcomes Outcomes included time to first stool, frequency of stool movements, consistency, dis-
tention, cramps, nausea and vomiting, as well as side effectsFollow-up were after two
days
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated random number list
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Open label
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-outs were balanced across treatment
groups with similar reasons for withdrawal
Selective reporting (reporting bias) Low risk Data reported appropriately
Other bias Low risk None apparent
Treepongkaruna 2014
Methods Randomised double-blind trial comparing PEG 4000 and lactulose
Participants 88 children aged between 12 to 36 months with a diagnosis of chronic functional con-
stipation based on a modification of the Rome II criteria for
infants and preschool children
Those with organic pathology were excluded
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Treepongkaruna 2014 (Continued)
Interventions Lactulose (3.3 g per day) for 4 weeks (n = 44)
PEG 4000 (Forlax®; 8 g per day) for 4 weeks.(n = 44)
Outcomes Primary outcome: stool frequency at week 4
Secondary outcomes: stool consistency, ease of stool passage and the occurrence of sub-
jective symptoms associated with defecation, including cramping, flatus, anal irritation,
adverse events and serious adverse events
Patients were followed up at weeks 2 and 4
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment was allocated using a randomi-
sation list of treatment allocation codes pre-
pared by the contract research organisation
responsible for operational management of
the study
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind, double-dummy
All sachets were similar in size, colour,
smell, taste and appearance in order to en-
sure adequate blinding of the study medi-
cation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop outs were balanced across interven-
tion groups with similar reasons for with-
drawal
Selective reporting (reporting bias) Low risk Data reported appropriately
Other bias Low risk None apparent
Urganci 2005
Methods Randomised open label trial of liquid paraffin versus lactulose
Participants 40 children 2 to 12 years old with constipation with evidence of faecal impaction were
enrolled in the study
Children with organic pathology were excluded
Interventions Liquid paraffin or lactulose 1 ml/kg, twice daily for each drug
For determination of the best dose for each child, parents were asked to increase or
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Urganci 2005 (Continued)
decrease the volume of each drug by 25% every 3 days as required, to yield two firm-
loose stools per day
The maximum dose used throughout the study was 3 mL/kg per day for each drug
All participants received behavioural advice and saw a nutritionist
Outcomes Primary outcome was effective treatment, defined as clearance of the impaction (more
than three bowel movements per week and improvement in stool consistency)
Secondary outcomes included stool frequency and stool consistency in first 4 weeks and
last 4 weeks, as well as adverse events
Follow-up was for 8 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Open label
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop outs
Selective reporting (reporting bias) Low risk Data reported appropriately
Other bias Low risk None apparent
Ustundag 2010
Methods Randomised trial comparing partially hydrolyzed guar gum (PHGG) to lactulose
Participants 68 children 4 to 16 years old with constipation (Rome III) were enrolled in the study
Those with organic pathology were excluded
Interventions Lactulose (1 ml/kg/day, in divided doses; n = 33) PHGG (n = 35) for children between
4-6 years: 3 g/day; 6-12 years: 4 g/day; and 12-16 years: 5 g/day
All patients received treatment for 4 weeks
Outcomes Primary outcome: frequency of defecation (number of stools per week)
Secondary outcomes: stool consistency, abdominal pain, stool withholding, rectal bleed-
ing, adverse events, and family questionnaire (satisfaction with success of treatment and
adverse effects)
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Ustundag 2010 (Continued)
Follow-up occurred at 4 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk During the treatment period, 7 patients
dropped out (4 from the PHGG group, 3
from the lactulose group)
Selective reporting (reporting bias) Unclear risk Adverse events were not adequately re-
ported
Other bias Low risk None apparent
Voskujl 2004
Methods Randomised double blind trial comparing PEG 3350 with lactulose
Participants 100 children aged six month to 15 years were included in this study
Children with an organic cause for their constipation were excluded
Interventions Patients had a 1 week run in and then received daily rectal enemas for 3 days (< 6 years
of age received 60 ml Klyx (sodium dioctylsulfosuccinate and sorbitol) while those > 6
years of age received 120 ml Klyx)
Lactulose (6 g (sachet)) versus PEG 3350 (2.95 g (sachet)) 1 sachet per day under 6
starting, 2 over 6 - children were reassessed at 1 week and either increase by 1 sachet or
decreased by 50%
Outcomes The primary outcomes were frequency of stools, frequency of encopresis, and overall
treatment success at eight weeks
An increase in defecation frequency was considered to have improved if it rose to three
or more times a week while encopresis had to decrease to an incidence of one episode or
less every two weeks
The incidence of adverse events was also documented
Follow-up was for 8 weeks
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Voskujl 2004 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Identical sachets, released by central phar-
macy
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop outs were balanced across interven-
tion groups with similar reasons for with-
drawal
Selective reporting (reporting bias) Low risk Data reported appropriately
Other bias Low risk None apparent
Wang 2007
Methods Randomised controlled multi-centre trial comparing PEG 4000 with lactulose
Participants 216 children from 8-18 years old
Children with other organic disease were excluded
Interventions PEG 4000 (n = 105): Forlax, 2 sachets x 20 g/day for 2 weeks
Lactulose (n = 111): 15 mL/day, then drop to 10 mL after 3 days) for 2 weeks
Outcomes Primary outcome was frequency of bowel movements
Secondary outcomes included stool consistency, abdominal symptoms and safety
Follow-up was for 2 weeks
Notes Chinese publication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A biostatistician constructed random digit
tables using statistical software SAS v8.2
Allocation concealment (selection bias) Unclear risk Not described
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Wang 2007 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Drop outs were not described
Selective reporting (reporting bias) Low risk Data reported appropriately
Other bias Low risk None apparent
PEG: polyethylene glycol.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bekkali 2011 Abstract publication
Trial compared one formulation of PEG to another (i.e. PEG 3350 with electrolytes versus PEG 4000)
Berg 1983 Study does not include patients with functional constipation
Patients were diagnosed with functional soiling
Bongers 2009 All patients received PEG
Trial compared enemas + PEG to PEG
Connolly 1974 Trial included adult and paediatric patients and did not report separate results for children
Trial compared an osmotic laxative (lactulose) to a stimulant laxative (i.e. senna, anthraquinone derivatives or
bisacodyl)
Corazziari 1996 Not a paediatric study
Dehghani 2014 All patients received PEG
Trial compared oral domperidone + PEG to PEG
Dupont 2006 Not a RCT, no comparison group
Ferguson 1999 Not a paediatric study
Hardikar 2007 Not a RCT, no comparison group
Hejl 1990 Not a RCT, no comparison group
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(Continued)
Kazak 1999 Children had underlying pathology
Khoshoo 2006 All patients received PEG 3350
Trial compared tegaserod + PEG 3350 to PEG 3350
Miller 2012 The trial focused on the treatment of faecal impaction rather than treatment of constipation
Ormarsson 2013 Abstract publication
Trial compared marine lipid suppositories to docusate sodium and sorbitol enema
Savino 2012 Trial compared one formulationof PEG to another (i.e. PEG-only formulation compared toPEGwith electrolytes)
Shevtsov 2005 Not a RCT
Sonheimer 1982 Not a RCT
Youssef 2002 The trial focused on the treatment of faecal impaction rather than treatment of constipation
PEG: polyethylene glycol.
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. PEG versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Frequency of defecation 2 101 Mean Difference (IV, Random, 95% CI) 2.61 [1.15, 4.08]
2 Serious adverse events 2 101 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.02, 1.63]
Comparison 2. PEG versus Lactulose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Frequency of defecation 6 465 Mean Difference (IV, Random, 95% CI) 0.70 [0.10, 1.31]
2 Need for additional therapies 4 304 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.36, 0.83]
3 Need for additional therapies
(sensitivity analysis)
4 304 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.33, 1.04]
4 Successful disimpaction 1 50 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [1.01, 1.53]
5 Adverse events 3 242 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.68, 1.11]
6 Serious adverse events 2 145 Risk Ratio (M-H, Fixed, 95% CI) 2.43 [0.37, 15.96]
Comparison 3. PEG versus Milk of Magnesia
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Frequency of defecation 4 261 Mean Difference (IV, Random, 95% CI) 0.20 [-0.68, 1.07]
2 Frequency of defecation
(sensitivity analysis excluding
outlier)
3 211 Mean Difference (IV, Fixed, 95% CI) 0.69 [0.48, 0.89]
3 Successful disimpaction 1 50 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.93, 1.16]
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Comparison 4. PEG versus Enema
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Frequency of defecation 1 80 Mean Difference (IV, Fixed, 95% CI) 1.00 [-1.58, 3.58]
2 Successful disimpaction 1 90 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.66, 1.09]
Comparison 5. PEG versus Liquid Paraffin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Frequency of defecation 2 261 Mean Difference (IV, Fixed, 95% CI) 0.35 [-0.24, 0.95]
Comparison 6. PEG versus Flixweed
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Frequency of defecation 1 109 Mean Difference (IV, Random, 95% CI) 0.0 [-0.33, 0.33]
2 Need for additional therapies 1 109 Risk Ratio (M-H, Fixed, 95% CI) 3.52 [1.03, 12.10]
Comparison 7. PEG versus Dietary fibre mix
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Frequency of defecation 1 83 Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.64, 1.04]
2 Need for additional therapy 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.05, 5.34]
3 Frequency of faecal incontinence 1 83 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.62, 0.42]
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Comparison 8. High dose PEG versus low dose PEG
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Frequency of defecation 1 90 Mean Difference (IV, Fixed, 95% CI) 1.30 [0.76, 1.84]
2 Need for additional therapy 1 90 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.24, 1.02]
3 Faecal incontinence 1 90 Risk Ratio (M-H, Fixed, 95% CI) 0.17 [0.02, 1.39]
4 Adverse events 1 90 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [0.33, 5.88]
Comparison 9. Liquid Paraffin versus Lactulose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Frequency of defecation 2 287 Mean Difference (IV, Fixed, 95% CI) 4.94 [4.28, 5.61]
Comparison 10. Lactulose versus Lactitol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Frequency of defecation 1 42 Mean Difference (IV, Fixed, 95% CI) -0.80 [-2.63, 1.03]
Comparison 11. Lactulose versus Milk of Magnesia
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Frequency of defecation 1 50 Mean Difference (IV, Fixed, 95% CI) -1.51 [-2.63, -0.39]
2 Need for additional therapy 1 50 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.80, 5.02]
3 Successful disimpaction 1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.67, 1.03]
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Comparison 12. Lactulose versus Partially Hydrolyzed Guar Gum
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Frequency of defecation 1 61 Mean Difference (IV, Fixed, 95% CI) 1.0 [-1.80, 3.80]
Analysis 1.1. Comparison 1 PEG versus placebo, Outcome 1 Frequency of defecation.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 1 PEG versus placebo
Outcome: 1 Frequency of defecation
Study or subgroup PEG Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Nurko 2008 26 5.96 (3.81) 24 2.42 (2.104) 39.3 % 3.54 [ 1.85, 5.23 ]
Thomson 2007 27 3.59 (2.26) 24 1.58 (1.131) 60.7 % 2.01 [ 1.04, 2.98 ]
Total (95% CI) 53 48 100.0 % 2.61 [ 1.15, 4.08 ]
Heterogeneity: Tau2 = 0.68; Chi2 = 2.38, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 3.49 (P = 0.00048)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 PEG versus placebo, Outcome 2 Serious adverse events.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 1 PEG versus placebo
Outcome: 2 Serious adverse events
Study or subgroup PEG Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Nurko 2008 0/26 3/24 54.0 % 0.13 [ 0.01, 2.44 ]
Thomson 2007 0/27 1/24 46.0 % 0.30 [ 0.01, 6.98 ]
Total (95% CI) 53 48 100.0 % 0.19 [ 0.02, 1.63 ]
Total events: 0 (PEG), 4 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 PEG versus Lactulose, Outcome 1 Frequency of defecation.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 2 PEG versus Lactulose
Outcome: 1 Frequency of defecation
Study or subgroup PEG Lactulose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Candy 2006 28 9.4 (4.56) 30 5.9 (4.29) 5.7 % 3.50 [ 1.22, 5.78 ]
Dupont 2005 51 7.24 (1.48) 45 7.21 (2.67) 18.3 % 0.03 [ -0.85, 0.91 ]
Gremse 2002 37 14.8 (1.4) 37 13.5 (1.5) 22.0 % 1.30 [ 0.64, 1.96 ]
Saneian 2012 25 3.56 (1.99) 25 3.16 (1.72) 16.0 % 0.40 [ -0.63, 1.43 ]
Treepongkaruna 2014 43 1.1 (0.55) 44 0.8 (0.41) 28.9 % 0.30 [ 0.10, 0.50 ]
Voskujl 2004 50 7.12 (5.14) 50 6.43 (3.08) 9.1 % 0.69 [ -0.97, 2.35 ]
Total (95% CI) 234 231 100.0 % 0.70 [ 0.10, 1.31 ]
Heterogeneity: Tau2 = 0.32; Chi2 = 15.92, df = 5 (P = 0.01); I2 =69%
Test for overall effect: Z = 2.29 (P = 0.022)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 PEG versus Lactulose, Outcome 2 Need for additional therapies.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 2 PEG versus Lactulose
Outcome: 2 Need for additional therapies
Study or subgroup PEG Lactulose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Candy 2006 0/28 8/30 17.0 % 0.06 [ 0.00, 1.04 ]
Dupont 2005 14/51 19/45 41.7 % 0.65 [ 0.37, 1.14 ]
Saneian 2012 4/25 10/25 20.7 % 0.40 [ 0.14, 1.11 ]
Voskujl 2004 9/50 10/50 20.7 % 0.90 [ 0.40, 2.02 ]
Total (95% CI) 154 150 100.0 % 0.55 [ 0.36, 0.83 ]
Total events: 27 (PEG), 47 (Lactulose)
Heterogeneity: Chi2 = 4.42, df = 3 (P = 0.22); I2 =32%
Test for overall effect: Z = 2.85 (P = 0.0044)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 PEG versus Lactulose, Outcome 3 Need for additional therapies (sensitivity
analysis).
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 2 PEG versus Lactulose
Outcome: 3 Need for additional therapies (sensitivity analysis)
Study or subgroup PEG Lactulose Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Candy 2006 0/28 8/30 3.9 % 0.06 [ 0.00, 1.04 ]
Dupont 2005 14/51 19/45 44.1 % 0.65 [ 0.37, 1.14 ]
Saneian 2012 4/25 10/25 22.1 % 0.40 [ 0.14, 1.11 ]
Voskujl 2004 9/50 10/50 30.0 % 0.90 [ 0.40, 2.02 ]
Total (95% CI) 154 150 100.0 % 0.59 [ 0.33, 1.04 ]
Total events: 27 (PEG), 47 (Lactulose)
Heterogeneity: Tau2 = 0.11; Chi2 = 4.42, df = 3 (P = 0.22); I2 =32%
Test for overall effect: Z = 1.84 (P = 0.066)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 PEG versus Lactulose, Outcome 4 Successful disimpaction.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 2 PEG versus Lactulose
Outcome: 4 Successful disimpaction
Study or subgroup PEG Lactulose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Saneian 2012 25/25 20/25 100.0 % 1.24 [ 1.01, 1.53 ]
Total (95% CI) 25 25 100.0 % 1.24 [ 1.01, 1.53 ]
Total events: 25 (PEG), 20 (Lactulose)
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.038)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 PEG versus Lactulose, Outcome 5 Adverse events.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 2 PEG versus Lactulose
Outcome: 5 Adverse events
Study or subgroup PEG Lactulose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Candy 2006 17/28 25/30 45.3 % 0.73 [ 0.52, 1.02 ]
Dupont 2005 2/51 3/45 6.0 % 0.59 [ 0.10, 3.36 ]
Treepongkaruna 2014 27/44 26/44 48.8 % 1.04 [ 0.74, 1.46 ]
Total (95% CI) 123 119 100.0 % 0.87 [ 0.68, 1.11 ]
Total events: 46 (PEG), 54 (Lactulose)
Heterogeneity: Chi2 = 2.30, df = 2 (P = 0.32); I2 =13%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 PEG versus Lactulose, Outcome 6 Serious adverse events.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 2 PEG versus Lactulose
Outcome: 6 Serious adverse events
Study or subgroup PEG Lactulose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Candy 2006 1/28 0/30 32.8 % 3.21 [ 0.14, 75.61 ]
Treepongkaruna 2014 2/43 1/44 67.2 % 2.05 [ 0.19, 21.75 ]
Total (95% CI) 71 74 100.0 % 2.43 [ 0.37, 15.96 ]
Total events: 3 (PEG), 1 (Lactulose)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 PEG versus Milk of Magnesia, Outcome 1 Frequency of defecation.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 3 PEG versus Milk of Magnesia
Outcome: 1 Frequency of defecation
Study or subgroup PEG MOM
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Gomes 2011 17 5 (1.56) 21 4.31 (1.89) 25.5 % 0.69 [ -0.41, 1.79 ]
Loening-Baucke 2006 39 9.7 (5.6) 40 9.7 (6) 9.2 % 0.0 [ -2.56, 2.56 ]
Ratanamongkol 2009 47 5.94 (0.652) 47 5.25 (0.32) 41.5 % 0.69 [ 0.48, 0.90 ]
Saneian 2012 25 3.56 (1.99) 25 4.67 (2.29) 23.8 % -1.11 [ -2.30, 0.08 ]
Total (95% CI) 128 133 100.0 % 0.20 [ -0.68, 1.07 ]
Heterogeneity: Tau2 = 0.47; Chi2 = 8.79, df = 3 (P = 0.03); I2 =66%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 PEG versus Milk of Magnesia, Outcome 2 Frequency of defecation (sensitivity
analysis excluding outlier).
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 3 PEG versus Milk of Magnesia
Outcome: 2 Frequency of defecation (sensitivity analysis excluding outlier)
Study or subgroup PEG MOM
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Gomes 2011 17 5 (1.56) 21 4.31 (1.89) 3.4 % 0.69 [ -0.41, 1.79 ]
Loening-Baucke 2006 39 9.7 (5.6) 40 9.7 (6) 0.6 % 0.0 [ -2.56, 2.56 ]
Ratanamongkol 2009 47 5.94 (0.652) 47 5.25 (0.32) 95.9 % 0.69 [ 0.48, 0.90 ]
Total (95% CI) 103 108 100.0 % 0.69 [ 0.48, 0.89 ]
Heterogeneity: Chi2 = 0.28, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 6.61 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 PEG versus Milk of Magnesia, Outcome 3 Successful disimpaction.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 3 PEG versus Milk of Magnesia
Outcome: 3 Successful disimpaction
Study or subgroup PEG MOM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Saneian 2012 25/25 24/25 100.0 % 1.04 [ 0.93, 1.16 ]
Total (95% CI) 25 25 100.0 % 1.04 [ 0.93, 1.16 ]
Total events: 25 (PEG), 24 (MOM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 PEG versus Enema, Outcome 1 Frequency of defecation.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 4 PEG versus Enema
Outcome: 1 Frequency of defecation
Study or subgroup PEG Enema
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bekkali 2009 39 8.7 (6.4) 41 7.7 (5.3) 100.0 % 1.00 [ -1.58, 3.58 ]
Total (95% CI) 39 41 100.0 % 1.00 [ -1.58, 3.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 PEG versus Enema, Outcome 2 Successful disimpaction.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 4 PEG versus Enema
Outcome: 2 Successful disimpaction
Study or subgroup PEG Enema Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bekkali 2009 30/44 37/46 100.0 % 0.85 [ 0.66, 1.09 ]
Total (95% CI) 44 46 100.0 % 0.85 [ 0.66, 1.09 ]
Total events: 30 (PEG), 37 (Enema)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Enema Favours PEG
Analysis 5.1. Comparison 5 PEG versus Liquid Paraffin, Outcome 1 Frequency of defecation.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 5 PEG versus Liquid Paraffin
Outcome: 1 Frequency of defecation
Study or subgroup PEG Paraffin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Karami 2009 48 4.7 (1.8) 55 4.5 (1.9) 69.5 % 0.20 [ -0.52, 0.92 ]
Rafati 2011 80 7 (3.8) 78 6.3 (3.1) 30.5 % 0.70 [ -0.38, 1.78 ]
Total (95% CI) 128 133 100.0 % 0.35 [ -0.24, 0.95 ]
Heterogeneity: Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 PEG versus Flixweed, Outcome 1 Frequency of defecation.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 6 PEG versus Flixweed
Outcome: 1 Frequency of defecation
Study or subgroup PEG Flixweed
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Nimrouzi 2015 53 5 (0.75) 56 5 (1) 100.0 % 0.0 [ -0.33, 0.33 ]
Total (95% CI) 53 56 100.0 % 0.0 [ -0.33, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours Flixweed Favours PEG
Analysis 6.2. Comparison 6 PEG versus Flixweed, Outcome 2 Need for additional therapies.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 6 PEG versus Flixweed
Outcome: 2 Need for additional therapies
Study or subgroup PEG Flixweed Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nimrouzi 2015 10/53 3/56 100.0 % 3.52 [ 1.03, 12.10 ]
Total (95% CI) 53 56 100.0 % 3.52 [ 1.03, 12.10 ]
Total events: 10 (PEG), 3 (Flixweed)
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.046)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 PEG versus Dietary fibre mix, Outcome 1 Frequency of defecation.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 7 PEG versus Dietary fibre mix
Outcome: 1 Frequency of defecation
Study or subgroup PEG Fibre
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Quitadamo 2012 47 5.8 (2) 36 5.6 (1.9) 100.0 % 0.20 [ -0.64, 1.04 ]
Total (95% CI) 47 36 100.0 % 0.20 [ -0.64, 1.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 PEG versus Dietary fibre mix, Outcome 2 Need for additional therapy.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 7 PEG versus Dietary fibre mix
Outcome: 2 Need for additional therapy
Study or subgroup PEG Fibre Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Quitadamo 2012 1/50 2/50 100.0 % 0.50 [ 0.05, 5.34 ]
Total (95% CI) 50 50 100.0 % 0.50 [ 0.05, 5.34 ]
Total events: 1 (PEG), 2 (Fibre)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 7.3. Comparison 7 PEG versus Dietary fibre mix, Outcome 3 Frequency of faecal incontinence.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 7 PEG versus Dietary fibre mix
Outcome: 3 Frequency of faecal incontinence
Study or subgroup PEG Fibre
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Quitadamo 2012 47 0.2 (1.3) 36 0.3 (1.1) 100.0 % -0.10 [ -0.62, 0.42 ]
Total (95% CI) 47 36 100.0 % -0.10 [ -0.62, 0.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 High dose PEG versus low dose PEG, Outcome 1 Frequency of defecation.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 8 High dose PEG versus low dose PEG
Outcome: 1 Frequency of defecation
Study or subgroup High dose PEG Low dose PEG
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dziechciarz 2015 44 6.5 (1.1) 46 5.2 (1.5) 100.0 % 1.30 [ 0.76, 1.84 ]
Total (95% CI) 44 46 100.0 % 1.30 [ 0.76, 1.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.70 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 High dose PEG versus low dose PEG, Outcome 2 Need for additional therapy.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 8 High dose PEG versus low dose PEG
Outcome: 2 Need for additional therapy
Study or subgroup High dose PEG Low dose PEG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dziechciarz 2015 8/44 17/46 100.0 % 0.49 [ 0.24, 1.02 ]
Total (95% CI) 44 46 100.0 % 0.49 [ 0.24, 1.02 ]
Total events: 8 (High dose PEG), 17 (Low dose PEG)
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 High dose PEG versus low dose PEG, Outcome 3 Faecal incontinence.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 8 High dose PEG versus low dose PEG
Outcome: 3 Faecal incontinence
Study or subgroup High dose PEG Low dose PEG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dziechciarz 2015 1/44 6/46 100.0 % 0.17 [ 0.02, 1.39 ]
Total (95% CI) 44 46 100.0 % 0.17 [ 0.02, 1.39 ]
Total events: 1 (High dose PEG), 6 (Low dose PEG)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
Test for subgroup differences: Not applicable
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Analysis 8.4. Comparison 8 High dose PEG versus low dose PEG, Outcome 4 Adverse events.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 8 High dose PEG versus low dose PEG
Outcome: 4 Adverse events
Study or subgroup High dose PEG Low dose PEG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dziechciarz 2015 4/44 3/46 100.0 % 1.39 [ 0.33, 5.88 ]
Total (95% CI) 44 46 100.0 % 1.39 [ 0.33, 5.88 ]
Total events: 4 (High dose PEG), 3 (Low dose PEG)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 Liquid Paraffin versus Lactulose, Outcome 1 Frequency of defecation.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 9 Liquid Paraffin versus Lactulose
Outcome: 1 Frequency of defecation
Study or subgroup Paraffin Lactulose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Farahmand 2007 127 13.1 (2.3) 120 8.1 (3.1) 95.2 % 5.00 [ 4.32, 5.68 ]
Urganci 2005 20 16.1 (2.2) 20 12.3 (6.6) 4.8 % 3.80 [ 0.75, 6.85 ]
Total (95% CI) 147 140 100.0 % 4.94 [ 4.28, 5.61 ]
Heterogeneity: Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 14.52 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 Lactulose versus Lactitol, Outcome 1 Frequency of defecation.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 10 Lactulose versus Lactitol
Outcome: 1 Frequency of defecation
Study or subgroup Lactulose Lactitol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Pitzalis 1995 23 4.8 (2.1) 19 5.6 (3.6) 100.0 % -0.80 [ -2.63, 1.03 ]
Total (95% CI) 23 19 100.0 % -0.80 [ -2.63, 1.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 Lactulose versus Milk of Magnesia, Outcome 1 Frequency of defecation.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 11 Lactulose versus Milk of Magnesia
Outcome: 1 Frequency of defecation
Study or subgroup Lactulose MOM
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Saneian 2012 25 3.16 (1.72) 25 4.67 (2.29) 100.0 % -1.51 [ -2.63, -0.39 ]
Total (95% CI) 25 25 100.0 % -1.51 [ -2.63, -0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.64 (P = 0.0084)
Test for subgroup differences: Not applicable
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Analysis 11.2. Comparison 11 Lactulose versus Milk of Magnesia, Outcome 2 Need for additional therapy.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 11 Lactulose versus Milk of Magnesia
Outcome: 2 Need for additional therapy
Study or subgroup Lactulose MOM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Saneian 2012 10/25 5/25 100.0 % 2.00 [ 0.80, 5.02 ]
Total (95% CI) 25 25 100.0 % 2.00 [ 0.80, 5.02 ]
Total events: 10 (Lactulose), 5 (MOM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 11.3. Comparison 11 Lactulose versus Milk of Magnesia, Outcome 3 Successful disimpaction.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 11 Lactulose versus Milk of Magnesia
Outcome: 3 Successful disimpaction
Study or subgroup Lactulose MOM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Saneian 2012 20/25 24/25 100.0 % 0.83 [ 0.67, 1.03 ]
Total (95% CI) 25 25 100.0 % 0.83 [ 0.67, 1.03 ]
Total events: 20 (Lactulose), 24 (MOM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
Test for subgroup differences: Not applicable
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Analysis 12.1. Comparison 12 Lactulose versus Partially Hydrolyzed Guar Gum, Outcome 1 Frequency of
defecation.
Review: Osmotic and stimulant laxatives for the management of childhood constipation
Comparison: 12 Lactulose versus Partially Hydrolyzed Guar Gum
Outcome: 1 Frequency of defecation
Study or subgroup Lactulose PHGG
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ustundag 2010 30 6 (4.3) 31 5 (6.64) 100.0 % 1.00 [ -1.80, 3.80 ]
Total (95% CI) 30 31 100.0 % 1.00 [ -1.80, 3.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours lactulose Favours PHGG
A P P E N D I C E S
Appendix 1. Search Strategy
Electronic searches
1. MEDLINE (1966 to March 11, 2016; National Library of Medicine, Bethesda, USA)
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. clinical trials as topic.sh.
6. randomly.ab.
7. trial.ti.
8. or/1-7
9. exp animals/ not humans.sh.
10. 8 not 9
11. exp constipation/
12. impaction.mp.
13. delayed bowel movement.mp.
14. obstipation.mp.
15. costiveness.mp.
16. defecation.mp.
17. bowel function*.mp.
18. bowel habit*.mp.
19. bowel movement*.mp.
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20. bowel symptom*.mp.
21. bowel motility.mp.
22. colon transit.mp.
23. evacuation.mp.
24. intestinal motility.mp.
25. stool*.mp.
26. or/11-25
27. laxative.mp.
28. (polyethylene glycol* OR macrogol* OR PEG OR Miralax OR Transipeg OR Movicol OR Forlax OR Idrolax OR GoLytely
OR PMF-100 OR Golitely OR Nulitely OR Fortans OR TriLyte OR Colyte OR lactulose OR disaccharide OR Apo-Lactulose
OR Chronulac OR lactitol OR sorbitol OR Generlac OR Cephulac OR Cholac OR Constilac OR Enulose OR cilac OR Heptalac
OR Actilax OR Duphalac OR Kristalose OR milk of magnesia OR magnesium hydroxide OR Magnesium citrate OR citroma OR
Osmoprep OR Visicol OR senna OR docusate sodium OR Sodium picosulphate OR Bisacodyl OR Cascara OR casanthranol OR
Buckthorn OR senokot OR Aloe Vera OR aloin Phenolphthalein OR Dulcolax OR osmotic).mp.
29. 27 OR 28
30. exp child/
31. exp infant/
32. exp adolescent/
33. (child* OR paediat* OR pediat* OR neonat* OR toddler OR young).mp.
34. OR/31-34
35. 10 AND 26 AND 29 AND 34
2. EMBASE (1984 to March 11, 2016; Elsevier Science, New York, USA)
1. random$.tw.
2. factorial$.tw.
3. (crossover$ or cross over$ or cross-over$).tw.
4. placebo$.tw.
5. single blind.mp.
6. double blind.mp.
7. triple blind.mp.
8. (singl$ adj blind$).tw.
9. (double$ adj blind$).tw.
10. (tripl$ adj blind$).tw.
11. assign$.tw.
12. allocat$.tw.
13. crossover procedure/
14. double blind procedure/
15. single blind procedure/
16. triple blind procedure/
17. randomized controlled trial/
18. or/1-17
19. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
20. 18 not 19
21. exp constipation/
22. impaction.mp.
23. delayed bowel movement.mp.
24. obstipation.mp.
25. costiveness.mp.
26. defecation.mp.
27. bowel function*.mp.
28. bowel habit*.mp.
29. bowel movement*.mp.
30. bowel symptom*.mp.
31. bowel motility.mp.
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32. colon transit.mp.
33. evacuation.mp.
34. intestinal motility.mp.
35. stool*.mp.
36. or/21-35
37. laxative.mp.
38. (polyethylene glycol* OR macrogol* OR PEG OR Miralax OR Transipeg OR Movicol OR Forlax OR Idrolax OR GoLytely
OR PMF-100 OR Golitely OR Nulitely OR Fortans OR TriLyte OR Colyte OR lactulose OR disaccharide OR Apo-Lactulose
OR Chronulac OR lactitol OR sorbitol OR Generlac OR Cephulac OR Cholac OR Constilac OR Enulose OR cilac OR Heptalac
OR Actilax OR Duphalac OR Kristalose OR milk of magnesia OR magnesium hydroxide OR Magnesium citrate OR citroma OR
Osmoprep OR Visicol OR senna OR docusate sodium OR Sodium picosulphate OR Bisacodyl OR Cascara OR casanthranol OR
Buckthorn OR senokot OR Aloe Vera OR aloin Phenolphthalein OR Dulcolax OR osmotic).mp.
39. 37 OR 38
40. exp child/
41. exp infant/
42. exp adolescent/
43. (child* OR paediat* OR pediat* OR neonat* OR toddler OR young).mp.
44. OR/40-43
45. 20 AND 36 AND 39 AND 44
3. Cochrane Central Register of Controlled Trials
#1MeSH descriptor: [Constipation] explode all trees
#2 (impaction OR “delayed bowel movement” or obstipation or costiveness or defecation or “bowel function” or “bowel habit” or
“bowel movement” or “bowel symptom” or “bowel motility” or “colon transit” or “evacuation” or “intestinal motility” or “stool”)
#3 MeSH descriptor: [Child] explode all trees
#4 MeSH descriptor: [Adolescent] explode all trees
#5 MeSH descriptor: [Infant] explode all trees
#6 child* or paediat* or pediat* or neonat* or toddler or young
#7 #3 or #4 or #5 or #6
#8 #1 or #3
#9 #7 and #8
4. Cochrane IBD Group Specialized Trials Register
1. Title/abstract: impaction OR “delayed bowel movement” or obstipation or costiveness or defecation or “bowel function” or “bowel
habit” or “bowel movement” or “bowel symptom” or “bowel motility” or “colon transit” or “evacuation” or “intestinal motility” or
“stool”
2. Title/abstract: child* or paediat* or pediat* or neonat* or toddler or young
3. 1 AND 2
WH A T ’ S N E W
Last assessed as up-to-date: 10 March 2016.
Date Event Description
10 March 2016 New search has been performed A new literature was conducted on 10 March 2016. New
studies added
10 March 2016 New citation required and conclusions have changed Updated review with some new conclusions and new au-
thors
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Constipation [∗drug therapy]; Defecation [drug effects; physiology]; Dietary Fiber [adverse effects; therapeutic use]; Lactulose [adverse
effects; therapeutic use]; Laxatives [adverse effects; ∗therapeutic use]; Magnesium Hydroxide [adverse effects; therapeutic use]; Mineral
Oil [adverse effects; therapeutic use]; Osmosis; Polyethylene Glycols [adverse effects; therapeutic use]; Randomized Controlled Trials
as Topic; Sugar Alcohols [adverse effects; therapeutic use]
MeSH check words
Adolescent; Child; Child, Preschool; Humans; Infant
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